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(57) ABSTRACT 
The present invention involves a novel tripyrrole dime 
thine-derived "expanded porphyrin' (texaphyrin), the 
synthesis of such compounds, their analogs or deriva 
tives and their uses. These expanded porphyrin-like 
macrocycles are efficient chelators of divalent and tri 
valent metal ions. Metal complexes of these compounds 
are active as photosensitizers for the generation of sin 
glet oxygen and thus potentially for inactivation or 
destruction of human immunodeficiency virus (HIV-1), 
mononuclear or other cells infected with such virus and 
tumor cells as well. A variety of texaphyrin derivatives 
have been produced and many more are readily obtain 
able. Various metal (e.g., transition, main group, and 
lanthanide) complexes with the texaphyrin and texaphy 
rin derivatives of the present invention have unusual 
water solubility and stability which render them partic 
ularly useful. These metallotexaphyrin complexes have 
optical properties making them unique as compared to 
existing porphyrin-like or other macrocycles. For ex 
ample, they absorb light strongly in a physiologically 
important region (i.e. 690-880 nm). These complexes 
also form long-lived triplet states in high yield and act 
as efficient photosensitizers for the formation of singlet 
oxygen. These properties, coupled with their high 
chemical stability and appreciable solubility in polar 
media such as water, add to their usefulness. 
12 Claims, 26 Drawing Sheets 
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EXPANDED PORPHYRNS: LARGE 
PORPHYRIN-LIKE ' 
TRPYRROLED METHINE-DERVED 
MACROCYCLES FOR SINGLET OXYGEN 
PRODUCTION 
This invention was made in part with government 
support under the following grants: National Science 
Foundation Presidential Young Investigator Award 
(1986) to J. L. Sessler, grant CHE-8552768; and NIH 
grant AI28845. The United States government has cer 
tain rights in the invention. 
This is a divisional of copending application Ser. No. 
07/771,393 filed on Sep. 30, 1991, now abandoned 
which is incorporated by reference herein. Application 
Ser. No. 07/771,383 is a continuation in part of Ser. No. 
O7/539,975, Jun. 18, 1990, now U.S. Pat. No. 5,162,509, 
which is a divisional of Ser. No. 07/320,293, Mar. 6, 
1989, now U.S. Pat. No. 4,935,498. 
The porphyrins and related tetrapyrrole macrocycles 
are among the most versatile of tetradentate ligands 
(see Example 1 for the references in this paragraph). 
Attempts to stabilize higher coordination geometries, 
however, with larger porphyrin-like aromatic macrocy 
cles have met with little success.25 Indeed, to date, only 
the uranyl complex of "superphthalocyanine" has been 
isolated and characterized structurally, although sev 
eral other large porphyrin-like aromatic macrocycles, 
including the "sapphyrins",36 "oxosapphyrins",67 
"platyrins's "pentaphyrin",9 and "(26porphyrin', 10 
have been prepared in their metal free forms. 
Although the porphyrins and related tetrapyrrolic 
compounds remain among the most widely studied of 
all known macrocycles, relatively little effort has been 
devoted to the development of larger conjugated pyr 
role containing systems2-12 (references cited in this para 
graph are shown in Example 2). Large, or "expanded” 
porphyrin-like systems, however, are of interest for 
several reasons: They could serve as possible aromatic 
analogues of the better studied porphyrins28 or serve as 
potential biomimetic models for these or other naturally 
occurring pyrrole-containing systems. In addition, 
large pyrrole containing systems offer exciting possibili 
ties as novel metal binding macrocyles.29-12, 15 For in 
stance, suitably designed systems could act as versatile 
ligands capable of binding larger metal cations and/or 
stabilizing higher coordination geometries, 16 than 
those routinely accommodated within the normally 
tetradentate ca. 2.0 A radius porphyrin core.7 The 
resulting complexes could have important application in 
the area of heavy metal chelation therapy, serve as 
contrast agents for magnetic resonanace imaging (MRI) 
applications, act as vehicles for radioimmunological 
labeling work, or serve as new systems for extending 
the range and scope of coordination chemistry. In 
addition, the free-base (metal-free) and/or diamagnetic 
metal-containing materials could serve as useful photo 
sensitizers for photodynamic therapeutic applications. 
In recent years a number of potentially pentadentate 
polypyrrolic aromatic systems, including the "sap 
phyrins",3,4 "oxosapphyrins", "smaragdyrins", 
platyrins,8 and "pentaphyrin” have been prepared and 
studied as their metal-free forms. For the most part, 
however, little or no information is available for the 
corresponding metallated forms. Indeed, the uranyl 
complex of "superphthalocyanine" was the only metal 












pared and characterized structurally. Unfortunately, 
the "superphthalocyanine' system is apparently not 
capable of existence in either its free-base or other met 
al-containing forms.2 Thus, prior to the present inven 
tion, no versatile, structurally characterized, pentaden 
tate aromatic ligands were available, although a num 
ber of nonaromatic pyridine-derived pentadentate sys 
tems had previously been reported. 920 
Gadolinium(III) complexes derived from strongly 
binding anionic ligands, such as diethylenetriamine pen 
taacetic acid (DTPA),1,2,3 1,4,7,10-tetraazacyclododec 
ane N,N',N,"N"-tetraacetic acid (DOTA), and 
1,10-diaza-4,7,13,16-tetraoxacyclooctadecane-N,N'-dia 
cetic acid (dacda), 6 are among the most promising of 
the paramagnetic contrast currently being developed 
for use in magnetic resonance imaging (MRI) (refer 
ences cited in this paragraph are shown in Example 3). 
Indeed, GdDTPA) is now undergoing clinical trials 
in the United States for possible use in enhanced tumor 
detection protocols. Nonetheless, the synthesis of other 
gadolinium(III) complexes remains of interest since 
such systems might have greater kinetic stability, supe 
rior relaxivity, or better biodistribution properties than 
the existing carboxylate-based contrast agents. One 
approach currently being pursued is based on using 
water-soluble porphyrin derivatives, such as tetrakis(4- 
sulfonatophenyl)porphyrin (TPPS).789 Unfortunately, 
the large gadolinium(III) cation cannot be accommo 
dated completely 10 within the relatively small prophy 
rin binding core (rs2.0 A), and, as a consequence, 
gadolinium prophyrin complexes are invariably hydro 
lytically unstable.78,12,13 Larger porphyrin-like ligands, 
however, might offer a means of circumventing this 
problem.14-22 
Acquired immunodeficiency syndrome (AIDS) and 
cancer are among the most serious public health prob 
lems facing our nation today. AIDS, first reported in 
1981 as occurring among male homosexuals, is a fatal 
human disease which has now reached pandemic pro 
portions (the references in this and the following four 
paragraphs are shown in Example 5). Cancer, in spite of 
some very significant advances in diagnostics and treat 
ment in recent years, remains the third leading cause of 
death in this country. Finding better ways to detect, 
treat, and reduce the transmission of these disorders are 
thus research objectives of the highest importance. 
One of the more promising new modalities currently 
being explored for use in the control and treatment of 
tumors is photodynamic therapy (PDT). This tech 
nique is based on the use of a photosensitizing dye, 
which localizes at, or near, the tumor site, and when 
irradiated in the presence of oxygen serves to produce 
cytotoxic materials, such as singlet oxygen (O2(Ag)), 
from otherwise benign precursors (e.g. (O2(Xg-)). 
Much of the current excitement associated with PDT 
derives from just this property: In marked contrast to 
current methods (e.g. conventional chemotherapy), in 
PDT the drugs themselves can (and should) be com 
pletely innocuous until "activated" with light by an 
attending physician. Thus a level of control and selec 
tivity may be attained which is not otherwise possible. 
At present, diamagnetic porphyrins and their deriva 
tives are considered the dyes of choice for PDT. It has 
been known for decades that porphyrins, such as hema 
toporphyrin, localize selectively in rapidly growing 
tissues including sarcomas and carcinomas, although 
the reasons for this selectivity remain recondite. Cur 
rently most attention is focusing on the so-called hema 
5,292,414 
3. 
toporphyrin derivative (HPD).2-57-21 an incompletely 
characterized mixture of monomeric and oligomeric 
porphyrins produced by treating hematoporphyrin di 
hydrochloride with acetic acid-sulfuric acid followed 
by dilute base.22-27 Fractions rich in the oligomeric 
species, which are believed to have the best tumor 
localizing ability,23.26 are marketed under the trade 
name Photofirin II (R) (PII) and are currently undergo 
ing phase III clinical trials for obstructed endobronchial 
tumors and superficial bladder tumors. Here, the mech 
anism of action is thought to be largely, if not entirely, 
due to the photoproduction of singlet oxygen (O2(A)), 
although alternative mechanisms of action, including 
those involving superoxide anion or hydroxyl and/or 
porphyrin-based radicals cannot be entirely ruled 
out.28-33 Promising as HPD is, it and other available 
photosensitizers (e.g., the phthalocyanines and napthap 
hthalocynines) suffer from serious disadvantages. 
While porphyrin derivatives have high triplet yields 
and long triplet lifetimes (and consequently transfer 
excitation energy efficiently to triplet oxygen),3b38 their 
absorption in the Q-band region often parallels that of 
heme-containing tissues. Phthalocyanines and naph 
thalocyanines absorb in a more convenient spectral 
range but have significantly lower triplet yields; more 
over, they tend to be quite insoluble in polar protic 
solvents, and are difficult to functionalize. Thus at pres 
ent the development of more effective photochemo 
therapeutic agents appears to require the synthesis of 
compounds which absorb in the spectral region where 
living tissues are relatively transparent (i.e., 700-1000 
nm), have high triplet quantum yields, and are mini 
mally toxic. The present inventors have recently repor 
ted (see Example 1) the synthesis of a new class of 
aromatic porphyrin-like macrocycles, the tripyr 
roledimethine-derived "texaphyrins', which absorb 
strongly in the tissue-transparent 730-770 nm range. 
The photophysical properties of metallotexaphyrins 
1-7c parallel those of the corresponding metallapor 
phyrins and the diamagnetic complexes 1-4 sensitize 
the production of O2 in high quantum yield. FIG. 19 
shows the schematic structure, metal complexes and 
derivatives of compounds of the present invention 
(1-7). 
Singlet oxygen is also believed to be the critical toxic 
species operative in experimental photsensitized blood 
purification procedures.3-39 This very new application 
of photodynamic therapy is of tremendous potential 
importance: It shows promise of providing a safe and 
effective means of removing enveloped viruses such as 
HIV-1, herpes simplex (HSV), cytomegalovirus 
(CMV), various forms of hepatitis-inducing virus, as 
well as other opportunistic blood-borne infections (e.g. 
bacteria and malaria plasmodium) from transfused 
whole blood. Given that AIDS is currently a not effec 
tively treated and usually fatal disease, the benefit of 
such a blood purification procedure would be of inesti 
mable value. 
At present, sexual relations and needle-sharing are the 
dominant mechanisms for the spread of AIDS. An 
increasing percentage of AIDS infections, however, are 
now occurring as a result of blood transfusions. 103 
Unfortunately, banked blood components are essential 
products for the practice of modern medicine and as a 
result this method of transmission is not likely to be 
precluded by simple changes in lifestyle. Rather, an 
absolutely fail-proof means must be developed to insure 












(and ideally all other blood-borne pathogens). To a 
certain extent this can be accomplished by screening the 
donors' histories and carrying out serologic tests. At 
present, however, the serologic tests for HIV-1 are 
insufficient to detect all infected blood samples, in par 
ticular, those derived from donors who have contacted 
the disease but not yet produced detectable an 
tibodies. 243 In addition, new mutants of the AIDS 
virus have been detected; some or all of which may 
escape detection by current means. Thus, an antiviral 
system is needed which removes any form of HIV-1 
from stored blood. This is particularly important since a 
stored blood sample from one infected donor could 
potentially end up being administered to several differ 
ent patients, in, for instance, the course of pediatric 
Ce, 
The present invention involves a novel tripyrrole 
dimethine-derived "expanded porphyrin' (texaphyrin), 
the synthesis of such compounds, their analogs or deriv 
atives and their uses. These expanded porphyrin-like 
macrocycles are efficient chelators of divalent and tri 
valent metal ions. Metal complexes of these compounds 
are effective as photosensitizers for the generation of 
singlet oxygen and thus potentially useful for the inacti 
vation or destruction of tumors as well as for the pro 
phylactic treatment and removal of human immunodefi 
ciency virus (HIV-1), and other viral contaminants 
from blood. A variety of texaphyrin derivatives have 
been produced and many more are readily obtainable. 
Various metal (e.g., lanthanide) complexes with the 
texaphyrin and texaphyrin derivatives of the present 
invention have unusual water solubility and stability 
which render them particularly useful. These metal 
lotexaphyrin complexes have optical properties making 
them unique as compared to existing porphyrin-like or 
other macrocycles. For example, they absorb light 
strongly in a physiologically important region (i.e. 
690-880 nm). Certain diamagnetic complexes also form 
long-lived triplet states in high yield and act as efficient 
photosensitizers for the formation of singlet oxygen. 
These properties, coupled with their high chemical 
stability and appreciable solubility in polar media such 
as water, add to their usefulness. 
The present invention relates to a class of compounds 
related to the basic compound having the structure: 
wherein R is H or CH3. This compound has been pre 






wherein M is H, L is absent and n is 0; or M is Cd, L is 
pyridine or benzimidazole and n is 1. 20 
A preferred compound of this invention is a cadmi 





A variety of texaphyrin derivatives and their metal 
complexes have been prepared and may be character 








M is H, R is H and n is 0; 
M is Cd-2, R is H and n is l; 
M is Ndi-3, R is H and n is 2; 65 
M is Sm3, R is H and n is 2; 
M is Eu3, R is H and n is 2; 
M is Gd+3, R is H, and n is 2; 
6 
M is Y-3, R is H, and n is 2; 
M is Int3, R is H, and n is 2; 
M is Zn2, R is H and n is l; 
M is Hg2, R is H, and n is 1. 
M is H, R is CH3 and n is 0; 
M is Gd+3, R is CH3 and n is 2; 
M is Eu3, R is CH3 and n is 2; 
M is Sm3, R is CH3 and n is 2; 
M is Y-3, R is CH3 and n is 2; or 
M is Int3, R is CH3 and n is 2. 
The present invention also includes a compound 
which may be described as having the structure: 
rt 
wherein 
M is Zn2, R and R' are H and n is l; 
M is Zn, R is H, R' is Ci and n is 1: 
M is Cd, R and R' are H and n is l; 
M is Cd, R is H, R' is Cl and n is 1; 
M is Mn, R and R' are H, and n is 1; 
M is Sm, R and R' are CH3 and n is 2; 
M is Eu, R and R' are CH3 and n is 2; or 
M is Gd, R and R' are CH3 and n is 2. 
In a broader view, the present invention involves a 
compound having the structure: 
n 
wherein R and R' are CH3; R is H and R' is OCH3; R is 
H and R' is Cl; R is H and R is COOH or R is H and R' 
is NO2; and wherein M is a divalent metal ion and n is 
1, or M is a trivalent metal ion and n is 2. 
In another view the texaphyrin and its derivatives 







wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. 
A particularly interesting texaphyrin analog of the 
present invention is one having the structure: 
wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. In the above-described 
metallic complexes M may be a divalent metal ion se 
lected from the group complexing of Cal-2, Mn+2, 
Co+2, Ni--2, Zn--2, Cd+2, Hgt-2, Smit-2 and UO2+2, 
(and n is 1) In certain aspects M is preferably Cd-2 or 
Zn2 or Hg2. When M is a trivalent metal ion, it is 
preferably selected from the group consisting of Mn+3, 
Co+3, Mn+3, Ni--3, Y+3, In+3, Pr-3, Nd-3, Sm--3, 
Eui-3, Gd+3, Gd+3, Tb-i-3, Dy+3, Er-3, Tm+3, Yb+3, 
Lu, and U+3; (and n is 2.) Most preferred trivalent 
metal ions are In-3, Y-3, Nd+3, Eu3, Sn+3 and 
Gd+3. 
Additionally, the compounds of the present invention 
may be described as having the structure: 
n 
R" 
wherein R and R' are F; R is H and R' is O(CH2C 
H2O)2CH3; R is H and R' is SO3 ; or R is H and R' is 
CO2 and M is a divalent metal ion and n is 1 or M is a 
trivalent metal ion and n is 2. 
A particularly preferred texaphyrin-derived com 
pound is one having the structure: 
-- 
CO2 
wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. 
In another aspect, the present invention involves a 
compound having the structure: 
rt -- 
wherein M is a divalent metal ion and n is l; or M is a 






phyrin derivatives of the present invention. So also is a 
compound having the structure: 
-- 
CO2 
wherein M is a divalent metal ion and n is 1 or M is a 
trivalent metal ion and n is 2. 
In yet another view, the present invention includes a 




wherein R1 and R2 are H or CH3 and M is Hg2, Cdt-2, 
Co+2 or Mn+2, and n is 1; or M is Ln+3, Gd+3, Y-3 or 
In+3 and n is 2; or R1 is H, R2 is Cl, Br, NO2, CO2H or 
OCH3, M is Znt2, Hg-2, Sn+2 or Cdt-2 and n is 1. 
Absent metal ions, compounds of the present inven 
tion may have the structure: 
O 











For example, a method for the synthesis of pentadentate 
expanded porphyrin compound is an aspect of the pres 
ent invention. This method comprises synthesizing a 
diformyl tripyrrane; condensing said tripyrrane with an 
ortho aryldiamine 1,2-diaminoalkene or 1,2-diaminoal 
kane; and oxidizing the condensation product to form a 
pentadentate expanded porphyrin compound. A pre 
ferred 1,2-diaminoalkene is diamisomaleonitrile. The 
ortho aryldiamine is preferably orthophenylenediamine 
or a substituted ortho phenylenediamine. Another pre 
ferred ortho aryldiamine is 2,3-diaminonaphthalene. 
Such a pentadentate expanded porphyrin compound is 
complexed with a metal and wherein a metal complex is 
produced by reaction of the pentadentate expanded 
porphyrin compound with metal ions. 
The present invention also involves a method of de 
activating retroviruses and enveloped viruses in blood. 
This method comprises adding a pentadentate expanded 
porphyrin analog metal complex as described above to 
blood and exposing the mixture to light to facilitate the 
formation of singlet oxygen. 
Photodynamic tumor therapy comprising administer 
ing a pentadentate expanded porphyrin analog com 
plexed with a metal to a tumor host and irradiating the 
analog in proximity to the tumor is another aspect of the 
present invention. 
A method for MRI enhancement comprising adminis 
tering a diamagnetic metalion (such as gadolinium, for 
example) complexed with texaphyrin or a texaphyrin 
derivative is also an aspect of the present invention. 
FIG. 1 shows a schematic structural view of Texa 
phyrin (1) and various complexes (2, 3 and 4). 
FIG. 2 shows a view of complex 4 (from FIG. 1) 
showing pyridine and macrocycle coordination to Cd. 
Ellipsoids scaled to the 40% probability level. The Cd 
ion lies in the plane of the nearly planar macrocycle 
(maximum deviation from planarity 0.10 (1) A). Rele 
vant Cd-N bond lengths (A) are as follows: 2.418(7), 
N1; 2.268(8), N8; 2.505(7), N13; 2.521(7), N20, 2.248(8), 
N23; 2.438(14), N1a; 2.473(12), N1b. Selected N-Cd-N 
bond angles (deg) are as follows: N1-Cd-N8, 78.9(2); 
N1-Cd-N23; 80.2(3); N8-Cd-N13, 68.4(2); N13-Cd-N20, 
64.4(2); N20-Cd-N23, 68.2(3); Nia-Cd-N1b, 176.1(4). 
FIG. 3 shows a view of complex 4 perpendicular to 
the plane through the macrocycle. Pyridine rings (not 
shown) lie perpendicular to the macrocycle with dihe 
dral angles of 88.5 (4) for ring a and 89.1 (3) for ring 
b. 
FIG. 4 shows a schematic representation of the re 




"texaphyrin' and representative five, six, and seven 
coordinate cadmium complexes (34-5) derived from 
this "expanded porphyrin'. 
FIG. 5 shows a view of the cation 54 showing pyri 
dine and macrocycle coordination to Cd. Ellipsoids are 
scaled to the 30% probability level. The cadmium (II) 
cation lies in the plane of the nearly planar macrocycle 
(max. deviation from planarity, 0.10(1) A). Relevant 
Cd-N bond lengths (A) are: 2,418(7) N1; 2.268(8) N8; 
2.505(7) N13; 2.521(7) N20, 2.248(8) N23; 2.438(14) 
N1a; 2.473(12) N1b. Selected N-Cd-N bond angles () 
are: 78.9(2) N1-Cd-N8; 802(3) N1-Cd-N23; 68.4(2) N8 
Cd-N13; 64.4(2) N13-Cd-N20; 68.2(3) N20-Cd-N23; 
176.1(4) N1a-Cd-N1b. For further structural details, see 
ref. 11. 
FIG. 6 shows a view of cation 44 showing the atom 
labelling scheme. Thermal ellipsoids are drawn to 30% 
probability level Relevant Cd-N bond lengths (A): N1 
2.462(13); N8 2.254(9); N13 2.535(13); N20 2.526(12); 
N23 2.298(11); N1A 2.310(9). Selected N-Cd-N bond 
angles (): N1-Cd-N878.3(4); N8-Cd-N13 67.8(4); N13 
Cd-N20 64.1(4); N20-Cd-N23 67.3(4); N1A-Cd-macro 
cycle N angles range from 93.7(4) to 100.4(3). The 
nitrate counter anion (not shown) is not coordinated to 
the Cd atom. 
FIG. 7 shows a view along the plane through the 
macrocycle illustrating the face-to-face stacking of the 
cation 4ba in the unit cell (macrocycle realted by 1 
x,y,z). The macrocycle mean planes are separated by 
3.38 A while the CdCd distance is 4.107(1) A. 
FIG. 8 shows a view of cation 44 perpendicular to 
the plane through the macrocycle (max. deviation 
0.154(13) A for C15). The Cd atom lies out this plane by 
0.334(2) A. BzIm (not shown) is oriented nearly perpen 
dicular to the macrocycle (dihedral angle of 86.3(3)) 
and lies over the pyrrole ring defined by C22, N23, C24, 
C25, and C26. 
FIG. 9 shows a UV-visible spectrum of 34NO3 
1.50X 10-5M in CHC13. 
FIG. 10 shows 1H NMR spectrum of 34NO3 in 
CDCl3. The signals at 1.5 and 7.26 ppm represent resid 
ual water and solvent peaks respectively. 
FIG. 11 shows a low field region of the 1H NMR 
spectra (in CDCl3) of 3A.NO3 (spectrum A) and the bulk 
inhomogeneous material from which crystals of com 
plex 4ba.NO3 were isolated (spectrum B). The signals 
marked "BzIn' ascribed to the bound benzimidazole 
ligand are observed at 6.4, 6.81, and 7.27 ppm; the sig 
nals marked 's' are due to residual solvent. 
FIG. 12 shows H NMR spectral titration of 34.NO3 
(initially 6.85X 10-3M in CDCl3) with increasing quan 
tities of BzIm showing moderate field region. The 
BzIm/ligand) ratios are 0,0.2,0.6, 2.8, 10, and 40 for 
traces A through F respectively, where BzIm) and 
ligand represent the total molar concentration of 
added benzimidazole and starting five-coordinate com 
plex 34.NO3. The chemical shifts for the BzIm signals in 
curve C (6.4, 6.62, 7.26 ppm) match well with those seen 
in the bulk sample from which the crystal of cation 4ba 
was isolated (c.f. spectrum B of FIG. 8). 
FIG. 13 shows the 1H NMR spectral titration of 
3.NO3 (initially 6.85X10-3M in CDCl3) with increas 
ing quantities of BzIn showing changes occurring in 
high field region. The BzIm)/ligand ratios are 0, 0.2, 
0.6, 2.8, 10, and 40 for traces A through Frespectively, 
where BzIm) and ligand) represent the total molar 
concentration of added benzimidazole and starting five 













FIG. 14 shows changes in the 1H NMR chemical shift 
of the "meso" signal for 34.NO3 plotted as a function of 
increasing BzIm). The terms BzIm) and ligand) repre 
sent the total molar concentration of added benzimid 
azole and starting five-coordinate complex 3A.NO3. 
FIG. 15 shows H NMR spectral titration of 34.NO3 
(initially 6.66X 10-3M in CDCl3) with increasing quan 
tities of pyridine showing changes occurring in high 
field region. The pyr/ligandratios are 0, 5, 10, 14, 20, 
and 40 for traces A through Frespectively. The terms 
pyr) and ligand represent the total molar concentra 
tion of added benzimidazole and starting five-coordi 
nate complex. 
FIG.16 shows changes in the 1H NMR chemical shift 
of the "meso' signal for 34NO3 as a function of increas 
ing pyr. The terms (pyr) and ligand represent the 
total molar concentration of added benzimidazole and 
starting five-coordinate complex 34.NO3. 
FIG. 17 shows metal complexes and derivatives 
(1B-11B) of compounds of the present invention. 
FIG. 18 shows the electronic spectrum of 2.B.(OH)2 in 
CHCl3. 
FIG. 19 schematically shows the structure, metal 
complexes and derivatives of compounds of the present 
invention (1-11). 
FIG. 20 shows the absorption spectrum of complex 
lcCl in deoxygenated methanol. The inset shows the 
fluorescence emission spectrum recorded in this same 
solvent. 
FIG. 21 shows the triplet-triplet transient difference 
spectrum of 1.Clin deoxygenated methanol recorded 1 
us after irradiation with a 10 ns pulse of 355 nm light (80 
m). The inset shows the rate of return to ground state, 
as monitored at 480 nm, and corresponds to a triplet 
lifetime of 67 us. 
FIG. 22 shows the spectral transmittance through 
human abdominal wall with a thickness of 22-32 mm 
(reference 47 taken from Example 5). 
FIG. 23 shows schematic structures of previously 
developed prophyrin derivatives potentially useful as 
photosensitizers. These include purpurins (1D); verdins 
(2D); benz-fused porphyrins (3D); and sulfonated phthal 
ocyanines and napthylocyanines (4D). 
FIG. 24 shows schematic structures of texaphyrin 
(5D); Sapphyrin (6D); platyrin (7D); vinylogous porphy 
rin (8D); and porphycenes (9D). 
FIG. 25 shows schematic structures of new aromatic 
tripyrroledimethine-derived macrocyclic ligands 
(10D-16D) analogous to texaphyrin (5D). 
FIG. 26 schematically (scheme 1) summarizes the 
synthesis of texaphyrin (5D). 
FIG. 27 shows schematic structures of extant and 
proposed texaphyrin derivatives (23 D-30D). 
FIG. 28 shows schematic structures of proposed me 
thine-linked texaphyrin derivatives (31D and 32D). 
FIG. 29 shows mononuclear cell killing by complexes 
1 and 34 without irradiation. Cell kill was determined 
by 3H-Thy uptake after phytohemagglutin (PHA) 
stimulation. 
FIG. 30 shows mononuclear cell killing by 1 g/ml 
complex 3A and irradiation. Cell kill was determined by 
H-Thy uptake after PHA stimulation. 
FIG. 31 shows expanded porphyrin-like macrocycles 
on hand. Alternatively to the pyrrolic hydrogen, a di 
or trivalent cation such as Cd2+, Zn2+, In3+, etc. may 
be bound. In this case, the complex could bear a net 
overall charge, i.e. + 1 for M+2 and +2 for M+3. 
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The present invention involves the synthesis of a 
novel "expanded porphyrin' system, 1B (to which the 
trivial name "texaphyrin' has been assigned), and in 
cludes description of the structure of the bispyridine 
adduct of its cadmium(II) complex. The presence in this 
structure of a near circular pentadentate binding core 
which is roughly 20% larger than that of the porphy 
rins, coupled with the realization that almost identical 
ionic radii pertain for hexacoordinate Cd?+ (r=0.92 A) 
and Gd3+ (r=0.94 A).25 prompted exploration of the 
general lanthanide binding properties of this new mo 
noanionic porphyrin-like ligand. The synthesis and 
characterization of a water-stable gadolinium(III) com 
plex derived formally from a new 16,17-dimethyl substi 
tuted analogue of the original "expanded porphyrin" 
system, as well as the preparation and characterization 
of the corresponding europium(III) and samarium(III) 
complexes. 
The aromatic "expanded porphyrin' system de 
scribed herein provides an important complement to the 
existing rich coordination chemistry of porphyrins. For 
instance, by using methods similar to those described, 
zinc(II), manganese(II), mercury(II), and neodymium 
(III) complexes have been prepared and characterized. 
The photophysical properties of this new series of 
tripyrroledimethine-derived "expanded porphyrins' 
("texaphyrins") are reported; these compounds show 
strong low energy optical absorptions in the 690-880 
nm spectral range as well as a high triplet quantum 
yield, and act as efficient photosensitizers for the pro 
duction of singlet oxygen, for example, in methanol 
solution. 
The present invention involves a major breakthrough 
in the area of ligand design and synthesis namely syn 
thesis of the first rationally designed aromatic pentaden 
tate macrocyclic ligand, a tripyrroledimethine-derived 
"expanded porphyrin'. This compound, to which the 
trivial name "texaphyrin' has been assigned, is capable 
of existing in both its free-base form and of supporting 
the formation of hydrolytically stable 1:1 complexes 
with a variety of metal cations, such as Cd2+, Hg2+, 
In3+, Y3+, Nd5+, Eu3+, Sm3+, and Gd3+, that are too 
large to be accommodated in a stable fashion within the 
20% smaller tetradentate binding core of the well-stud 
ied porphyrins. In addition, since the free-base form of 
texaphrin is a monoanionic ligand, the texaphyrin com 
plexes formed from divalent and trivalent metal cations 
remain positively charged at neutral pH. As a result, 
many of these complexes are quite water soluble-at 
least far more so than the analogous porphyrin com 
plexes. 
The results to date, some of which are summarized 
herein, indicate strongly that the expanded porphyrin 
like macrocycles of the present invention should be 
efficient photosensitizers for the destruction of free 
HIV-1 and for the treatment of tumors in vivo and 
infected mononuclear cells in blood. Altering the polar 
ity and electrical charges of side groups of these macro 
cycles is anticipated to alter markedly the degree, rate, 
and perhaps site(s) of binding to free enveloped viruses 
such as HIV-1 and to virally-infected peripheral 
mononuclear cells. These substituent changes are also 
expected to modulate photosensitizer take-up and pho 
tosensitization of leukemia or lymphoma cells contami 














The porphyrins and related tetrapyrrole macrocycles 
are among the most versatile of tetradentate ligands. 
Attempts to stabilize higher coordination geometries, 
however, with larger porphyrin-like aromatic macrocy 
cles have met with little success. Indeed, to date, only 
the uranyl complex of "superphthalocyanine' has been 
isolated and characterized structurally, although sev 
eral other large porphyrin-like aromatic macrocycles, 
including the "sapphyrins",36 "oxosapphyrins',6,7 
"platyrins' "pentaphyrin',9 and "26porphyrin',10 
have been prepared in their metal free forms. This ex 
ample describes one aspect of the development of a new 
type of "expanded porphyrin' capable of binding a 
variety of metal cations. Also described herein is the 
original synthesis of compound an unprecedented 
porphyrin-like aromatic pentadentate ligand,22 and the 
structure of its cadmium (II) bispyridine complex 4. 
(See FIG. 1 for the structure of compound or complex 
1-4) 
The present involves preparation of the nonaromatic 
methylene-bridged macrocycle (compound 1) by the 
direct acid-catalyzed condensation of 2,5-bis(3-ethyl-5- 
formyl-4-methylpyrrol-2-yl)methyl-3,4-diethyl-pyrrole 
and orthophenylenediaminel3 and determined it to be an 
ineffective cheland. The present inventors have now 
found that stirring the reduced macrocyclic compound 
1 with cadmium chloride for 24 hours in chloroform 
methanol (1:2 v.v.) in the presence of air, followed by 
chromatographic purification on silica gel and recrys 
tallization from chloroform-hexanes, gives the cadmi 
um(II) complex 3.Cl in 24% yield as a dark green pow 
der. 15 Under the reaction conditions both ligand oxida 
tion and metal complexation take place spontaneously. 
The structure of compound 3 suggests that it can be 
formulated as either an 18 at-electron benzannelated 
18annulene or as an overall 22 7t-electron system; in 
either case an aromatic structure is defined. The proton 
NMR spectrum of complex 3.Cl is consistent with the 
proposed aromaticity. For the most part, complex 3.Cl 
shows ligand features which are qualitatively similar to 
those observed for compound 1. As would be expected 
in the presence of a strong diamagnetic ring current, 
however, the alkyl, imine, and aromatic peaks are all 
shifted to lower field. Furthermore, the bridging methy 
lene signals of compound 1 (at 84.0) are replaced by 
a sharp singlet, at 11.3 ppm, ascribable to the bridging 
methine protons. The chemical shift of this "meso' 
signal is greater than that observed for CdCOEP)16 
(6s 10.0), 17 an appropriate 18 at-electron aromatic refer 
ence system, and is quite similar to that observed for the 
free-base form of decamethylsapphyrin (6:11.5-11.7),3 
a 22 at-electron pyrrole-containing macrocycle. 
The optical spectrum of complex 3.Cl bears some 
resemblance to those of other aromatic pyrrole-contain 
ing macrocyles3.67.18 and provides further support for 
the proposed aromatic structure. The dominant transi 
tion is a Soret-like band at 424 nm (e=72,700), which is 
considerably less intense than that seen for CdCOEP)- 
(pyr) 16 Amax=421 nm, e=288,000). This peak is 
flanked by exceptionally strong N- and Q-like bands at 
higher and lower energies. As would be expected for a 
larger at system, both the lowest energy Q-like absorp 
tion (Wax=767.5 nm, e = 41,200) and emission 
(Anax=792 nm)) bands of complex 3.Clare substantially 
red-shifted (by ca. 200 nm) as compared to those of 
typical cadmium porphyrins. 18.19 
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When the above metal insertion was repeated with 
cadmium nitrate, a complex was obtained in roughly 
30% yield, which, on the basis of microanalytical da 
ta, was formulated as the protonated complex 
3.NO3.(HNO3). Upon treatment with excess pyridine 
and recrystallization from chloroform-hexane, the bis 
pyridine adduct complex 4-NO3, with spectral proper 
ties essentially identical with 3.Cl, was isolated as dark 
green crystals. The molecular structure of 4-NO3, 
determined by X-ray diffraction analysis, confirms the 
aromatic nature of the ligand (FIG. 2).20 The central 
five nitrogen donor atoms of complex 4 are essentially 
coplanar and define a near circular cavity with a center 
to-nitrogen radius of ca. 2.39 A (cf. FIG. 3), which is 
roughly 20% larger than that found in metallopor 
phyrins.2. The Cd atom lies in the plane of the central 
Ns binding core. The structure of the "expanded por 






1. The Porphyrins; Dolphin, D., Ed.; Academic Press: 
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phthalocyanine-like system was prepared by a uranyl 
medicated condensation; it is not obtainable as the 
free-base or in other metal-containing forms: (a) Day, 
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CdTPP1622 or CdTPP-(dioxane)2,23 in which the cad- 20 4. For an example of a porphyrin-like system with a 
mium atom lies out of the porphyrin N4 donor plane (by 
0.58 and 0.32 A, respectively). Moreover, in contrast to 
cadmium porphyrins, for which a five-coordinate 
square-pyramidal geometry is preferred and to which 
only a single pyridine molecule will bind, in complex 
4-NO3 the cadmium atom is seven-coordinate, being 
complexed by two apical pyridine ligands. The configu 
ration about the Cd atom is thus pentagonal bipyrim 
idal; a rare but not unknown geometry for cadmium(II) 
complexes.25 
Under neutral conditions complexes 3 and 4 appear to 
be more stable than cadmium porphyrins: Whereas 
treatment of CdTPP or CdTPP(pyr) with aqueous 
Na2S leads to cation loss and precipitation of CdS, in 
the case of complexes 3 and 4 no demetallation takes 
place. (Exposure to aqueous acid, however, leads to 
hydrolysis of the macrocyle.) Indeed, it has not been 
possible to prepare the free-base ligand 2 by demetalla 
tion. The tripyrroledimethine-derived free-base ligand 2 
was synthesized directly from 1 by stirring in air 
saturated chloroform-methanol containing N,N,N'-tet 
ramethyl-1,8-diaminonaphthalene. Although the yield 
is low (s.12%).26 once formed, compound 2 appears to 
be quite stable: It undergoes decomposition far more 
slowly than compound 1.3 Presumably, this is a reflec 
tion of the aromatic stabilization present in compound 2. 
A further indication of the aromatic nature of the free 
base "expanded porphyrin' 2 is the observation of an 
internal pyrrole NH signal at 6=0.90, which is shifted 
upfield by over 10 ppm as compared to the pyrrolic 
protons present in the reduced macrocyle 1.3 This shift 
parallels that seen when the sp3-linked macrocycle, 
octaethylporphyrinogen (6(NH)= 6.9),27 is oxidized to 
the corresponding porphyrin, H2OEP (6 
(NH)= -3.74).7 This suggests that the diamagnetic 
ring current present in compound 2 is similar in strength 
to that of the porphyrins. 
The aromatic "expanded porphyrin' system de 
scribed herein provides an important complement to the 
existing rich coordination chemistry of porphyrins. For 
instance, by using methods similar to those described, 
zinc(II), manganese(II), mercury(II), and neodymium 
(III) complexes of compound 215 have been prepared 
and characterized. 
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rected for decay, Lp effects, and absorption. Refined 
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Lett. 1969, 42,3711-3714. 
EXAMPLE 2 
Although the porphyrins and related tetrapyrrolic 
compounds remain among the most widely studied of 
all known macrocycles, relatively little effort has been 
devoted to the development of larger conjugated pyr 
role containing systems.22 Large, or "expanded" por 
phyrin-like systems, however, are of interest for several 
reasons: They could serve as possible aromatic ana 
logues of the better studied porphyrins or serve as 
potential biomimetic models for these or other naturally 
occurring pyrrole-containing systems. 3. In addition, 
large pyrrole containing systems offer exciting possibili 
ties as novel metal binding macrocyles.292. For in 
stance, suitably designed systems could act as versatile 
ligands capable of binding larger metal catiohs and/or 
stabilizing higher coordination geometries than 
those routinely accommodated within the normally 
tetradentate ca. 2.0 A radius porphyrin core." The 
resulting complexes could have important application in 
the area of heavy metal chelation therapy or as new 
vehicles for extending the range and scope of coordina 
tion chemistry. 15, 18 In recent years a number of poten 
tially pentadentate polypyrrolic aromatic systems, in 
cluding the "sapphyrins", "oxosapphyrins", "sma 
ragdyrins',3' platyrins,8 and "pentaphyrin'7 have been 
prepared and studied as their metal-free forms. For the 
most part, however, little or no information is available 
for the corresponding metallated forms. Indeed, the 
uranyl complex of "superphthalocyanine' was the only 
metal-containing pentapyrrolic system which has been 
prepared and characterized structurally. Unfortu 
nately, the "superphthalocyanine' system is apparently 
not capable of existence in either its free-base or other 
metal-containing forms.2 Thus, prior to the present in 
vention, no versatile, structurally characterized, penta 
dentate aromatic ligands were available, although a 
number of nonaromatic pyridine-derived pentadentate 
systems had previously been reported.1920 The aspect 
of this invention described here further shows develop 
ment of a new class of pyrrole-derived aromatic "ex 
panded porphyrins' capable of binding a variety of 
metal cations and stabilizing a range of unusual coordi 
nation geometries. The present inventors have recently 
communicated the synthesis of compound 24, 11 (see 
Example 1) an unprecedented porphyrin-like monoan 
ionic aromatic pentadentate ligand to which has been 
assigned the trivial name "texaphyrin' (for large Texas 
style porphyrin), 18 and the structure of its seven coordi 
nate cadmium(II) bispyridine pentagonal bipyramidal 
complex 5a. Due to the importance of cadmium com 
plexes in possible chelation based therapeutic applica 
tions21,22 and as potential structural probes for natural 
metalloproteins (e.g. employing 13Cd NMR spectro 
scopy), the coordination properties of the cadmium 
containing "texaphyrin" system were investigated fur 
ther. The present example reports the characterization 
by single crystal X-ray diffraction analysis of a monoli 
gated six coordinate cadmium(II) benzimidazole pen 
tagonal pyramidal cationic complex 4bA corresponding 
formally to a coordinatively unsaturated analogue of 
5aA. The present description, which includes the results 
of solution base binding (Ken) studies for both pyridine 
(pyr) and benzimidazole (BzIm), constitutes the first 
structurally documented instance wherein the same 
macrocyclic ligand has been used to support these two 
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rare, but not unknown, 9 coordination geometries about 
the same metal cation.2 See FIG. 4 for the schematic 
structure of compounds and complexes of the present 
invention referred to here as 14, 24, 34, 4aa, 4ba, 5a 
and 5bA. 
Treatment of the reduced, sp3 form of the macrocyle 
(14) with cadmium chloride or cadmium nitrate in 
air-saturated chloroform-methanol leads in both cases 
to the formation of green solutions. Following chro 
matographic purification on silica gel and recrystalliza 
tion from chloroform-hexanes, the five-coordinate "tex 
aphyrin" chloride or nitrate complexes 34.Cl and 34 
NO3 were obtained in analytically pure form (as the 
demihydrates) in roughly 25% yield. When, however, 
the metal insertion procedure was carried out (using 
cadmium nitrate) under reaction and purification condi 
tions identical to those described above, with the excep 
tion that chromatography was effected on SEPHA 
DEX, a mixture of crystalline and noncrystalline green 
solids was obtained. Treatment of this apparently inho 
nogeneous bulk material, which failed to analyze as a 
pure five coordinate complex, with excess pyridine and 
recrystallization from chloroform-hexanes produced 
the bispyridine complex 5a-NO3 as dark green crystals 
in essentially quantitative yield. As communicated ear 
lier, (see Example 1) an X-ray crystal diffraction anal 
ysis served to confirm the pentagonal bipyramidal coor 
dination geometry postulated for this bisligated seven 
coordinate complex and the planar pentadentate nature 
of the macrocyclic "texaphyrin' ligand 2A (c.f. FIG. 5). 
As a first step towards determining the nature of the 
above intermediate product, a single crystal was iso 
lated from the inhomogeneous solid mixture and subject 
to an X-ray diffraction analysis. The structure so ob 
tained (FIG. 6) was quite unexpected: It revealed a six 
coordinate pentagonal pyramidal cadmium(II) complex 
(4b.A.NO3) wherein one of the two possible axial ligation 
sites is occupied by a bound benzimidazole (BzIm) with 
the nitrate counter anion not being coordinated to the 
central Cd atom. The first donor nitrogens of the penta 
dentate "texaphyrin' macrocycle then serve to com 
plete the coordination sphere about cadmium. As 
shown in FIG. 6, the 5 donor atoms of the ligand are 
bound to the Cd atom which lies out of the plane of the 
macrocycle being displaced by 0.338(4) A from the N5 
donor plane towards the coordinated nitrogen of the 
benzimidazole ligand. This out of plane distance, which 
is similar to that seen in CdTPP-(dioxane)225 (0.32 A)26 
(but smaller than that observed in CdTPP27), is in 
marked contrast to that observed for the corresponding 
bispyridine pentagonal bipyramidal adduct 5a-NO3.11 
In this earlier structure, the cadmium(II) cation was 
found to lie essentially within the plane of macrocycle 
(c.f. FIG. 5). Cation 4ba further differs from 5a in that, 
within the crystal lattice, two molecules stack on one 
another in a face-to-face fashion (FIG. 7) being sepa 
rated by van der Waals' distances of ca. 3.38 A. As a 
result, the alkyl groups in any given molecule are all 
displaced to the BzIm-bearing side of the macrocyclic 
plane. In common with the bispyridine structure, 
however, in cation 4ba the sp2 atoms of the macrocycle 
are all essentially planar (FIG. 8) with the maximum 
deviation from planarity (0.154(13) A) being found for 
C11. Also in common with complex 5a-NO3, the five 
ligand nitrogens define a near circular binding cavity 
with a center-to-nitrogen radius of ca. 2.42 A, which is 













The above structural results support the original for 
mulation of "texaphyrin' 2A as a large 22 at-electron (or 
benzannelated 18 at-electron) aromatic porphyrin-like 
ligand.28 They also clearly demonstrate that this "ex 
panded porphyrin' is capable of supporting more than 
one kind of "unusual' coordination geometry about 
cadmium. 
The above structural results also provide insight into 
the nature of the inhomogeneous cadmium-containing 
intermediate obtained following metal insertion and 
sephadex-based purification: At least a portion of this 
material consists of the six-coordinate BzIm ligated 
complex 4b.NO3. Although it is certainly plausible to 
postulate that the coordinated BzIm in cation 4ba de 
rives from ligand degradation reactions associated with 
metal insertion and accompanying oxidation (presum 
ably involving electrophilic aromatic deacylation of an 
tripyrrane a-carbon and subsequent condensation with 
ortho-phenylene diamine), the observation of this six 
coordinate species does not establish unambiguously 
that such Bz.In coordination is chemically reasonable. 
This point is of particular interest since in the presence 
of excess pyridine, it is the bisligated seven coordinate 
cationic species 5a, which is favored in the solid state. 
It was believed to be of importance to determine the 
solution binding properties of compound 34.NO3 in the 
presence of both benzimidazole and pyridine. The ob 
jective was not only to probe the ligation differences (if 
any) of these two axial bases but also to define further 
the nature of the intermediate inhomogeneous solid 
material formed following Cd insertion and SE 
PHADEX-based purification, testing in particular the 
reasonable assumption that this material consists of a 
mixture of the five and six coordinate cations 34 and 
4b.A. 
For a rigorously five coordinate starting cadmium 
complex, such as that represented schematically by 
structure 34, where neither the counter anion nor ad 
ventitious ligands serves to occupy an apical coordina 
tion site, base binding can be considered to occur in 
accord with equations (1) and (2) shown below. Under 
conditions where K2K2, these processes can be con 
sidered to occur sequentially, giving first a monoli 
gated, presumably pentagonal pyramidal six coordinate 
species (such as 4b), followed by a coordinatively 
saturated bisligated pentagonal bipyramidal product 
akin to 5aa. Where, however, K2>>K this stepwise 
conceptual approach is invalid. Under these conditions, 
it becomes easier to analyze the base binding in terms of 





In the context of the present study therefore the prob 
len becomes one of finding a solution-based analytical 
method that will allow changes associated with mono 
and bis ligation to be probed, and using the accompany 
ing changes to determine as appropriate Ki, K2, or 
KK2. 
Optical spectroscopy is an important method of char 
acterization for nonlabile metal complexes. In cases 
where absorption changes accompany ligand binding, 
optical spectroscopy also provides a convenient means 
of determining base binding constants.29 In the case of 
cadmium tetraphenyl porphyrin (CdTPP), for instance, 
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Miller and Dorough,30 by monitoring the changes asso 
ciated with the two low energy Q bands of the absorp 
tion spectrum, determined a value for the binding of a 
single pyridine axial ligand to the unligated four-coordi 
nate starting metalloporphyrin in benzene at 29.9" (K1) 
of roughly 2,700M. Interestingly, these30 and later 
workers obtained no evidence for the formation of a 
bisligated CdTPP-(pyr)225 species. Thus, although a 
pseudo octahedral coordination geometry is defined in 
the solid state by the weakly bound axial ligands of 
CdTPP-(dioxane)2.26 there is no evidence that such a 
structure is attained in pyridine-containing benzene 
solution. 
The optical spectrum of purified complex 34NO3 
(FIG. 9) bears some elements in common with that of 
cadmium porphyrins.303 For instance, complex 34 
NO3 in CHCl3 displays a strong Soret-like high energy 
transition at 425 nm (e=82,800) which is considerably 
less intense than that seen in cadmium porphyrins (e.g. 
CdCEP:25 Ana (CHCl3/MeOH v/v 19/1)=406 nm, 
e=272,000). This complex also displays exceptionally 
strong flanking N- and Q-like bands at higher and lower 
energy. The lowest energy Q-like band (Anax=770 nm, 
e=49,800) is particularly noteworthy: It is shifted to the 
red by ca. 200 nm and is almost a factor of four more 
intense than the lowest energy Q-type transition seen in 
typical cadmium porphyrins (e.g. CdCEP: Anax 
(CHCl3/MeOH v/v 19/1)=571 nm, e = 15,400).35 We 
consider such behavior to be reflective of the larger 
delocalized aromatic system present in the overall 22 
T-electron "texaphyrins' than in the 1877-electron por 
phyrins. Interestingly, the lowest energy transition seen 
in the cadmium complex of 3,8,12,13,17,22-hexaethyl 
2,7,18,23-decamethylsapphyrin in CHCl3 is 701 nm,35 
whereas that seen for the uranyl complex of "superph 
thalocyanine" is 914 nm.2 Thus the lowest energy tran 
sition of 34.NO3 lies intermediate in energy between 
those observed for these two very different 22 at-elec 
tron pentapyrrolic reference systems. 
Unfortunately, in spite of the gross qualitative resem 
blance between the optical spectrum of 34.NO3 and the 
other pyrrole-containing aromatic macrocycles de 
scribed above, optical spectroscopy has proved to be an 
ineffective means of determining the axial ligation prop 
erties of cation 34. For instance, addition of excess pyri 
dine to a solution of 34.NO3 in CHC3 caused only a ca. 
1.5 nm red shift in the Soret-like band and a 3.5 nm blue 
shift of the lowest energy Q-type band. (Similar insignif. 
icant changes are also observed upon BzIn addition.) 
Thus, at least in the case of the cadmium complexes, the 
optical properties of the "texaphyrin' expanded por 
phyrin system appear to be largely determined by the 
overall macrocyclic skeleton and relatively insensitive 
to changes in the electron environment of the bound 
cation. 
Cadmium(II) complexes of "texaphyrin' 24 are dia 
magnetic and hence readily susceptible to study by H 
NMR methods. As shown in FIG. 10, the 1H NMR of 
3A.NO3 shows general features which are typical of 
those expected for a large aromatic pyrrole-containing 
macrocycle. For instance, as compared to the sp3 form 
of the ligand (1) the alkyl, imine, and aromatic peaks 
are all shifted to lower field. Even more diagnostic, 
however, are the presence of "meso" signals ascribable 
to the bridging sp2 hybridized methine protons in both 
the free base "texaphyrin' 2 and its various cadmium 
containing derivatives 3-5. These bridging protons res 













bridging methylene signals of the original sp form of 
the ligand (14). In fact, the "meso" signals of 34.NO3 
is found roughly 1 ppm down field from these of typical 
R-alkyl substituted cadmium porphyrins (e.g. CdCO 
EP).25,366-10.0) and approach in value the chemical 
shifts observed for diamagnetic sapphyrins (e.g., for 
free-base decamethylsapphyrine, 8s 11.5-11.7). Such 
observations are not unexpected in light of the highly 
delocalized at character postulated for the 22 at-elec 
tron "texaphyrin' systems. 
FIG. 11 provides a comparison of the low field re 
gion of the H NMR spectra of 34.NO3 and the crude 
material from which the crystals of cation 4b were 
obtained. The most striking difference between these 
two spectra is the presence of small broad signal at ca. 
6.4 ppm and two sharper, more pronounced peaks at 
6.81 and 7.27 ppm in the spectrum of the bulk material 
(trace B in FIG. 11). Although it is tempting to assign 
these features as signals arising from bound BzImpres 
ent in cation 4b, this conclusion is not necessarily obvi 
ous: The carbon-bound protons of free BzIm in CDCl3 
resonate at 7.25 (m, 2H), 7.75 (m, 2H), and 8.41 (s, 1H) 
ppm. Although shifts to higher field is expected on 
binding to cation 34, it is not clear that the expected 
changes would be as large as those actually observed. A 
complete spectral titration of complex 34NO3 with 
BzIm was therefore undertaken in an effort to address 
this matter and to assign unambiguously the 6.4, 6.81, 
and 7.27 ppm signals. The results of these titrations are 
given in FIGS. 12 and 13. 
A striking feature of the 1H NMR titration shown in 
FIG. 12 is the dramatic change in chemical shift that 
occurs for the BzIn signals upon complexation to cat 
ion 3A. Equally important, however, is the observation 
that the qualitative features of the bulk cadmium con 
taining material discussed above (c.f. F.G. 11, spectrum 
B) are reproduced upon the addition of roughly 3/5 
equivalents of BzIm to purified 34.NO3! This dramatic 
result provides, in our estimation, unambiguous support 
for the structural assignment of cation 4ba made on the 
basis of X-ray diffraction analysis. It also confirms quali 
tatively the original supposition that the inhomogene 
ous material isolated after Cd insertion and Sephadex 
purification does indeed involve an admixture of five 
and six coordinated species (i.e. 34.NO3 and 4b.NO3). 
For quantitative Ke determinations it proved easiest 
to monitor the changes associated with the "meso' 
signals. Here, sharp peaks, indicative of fast ligand ex 
change,2938 and reasonably large changes in chemical 
shift were observed (FIG. 13). In addition, no interfer 
ing BzIm-based resonances are found in this region. In 
FIG, 14 the changes in chemical shift for the "meso' 
protons in complex 34.NO3 are plotted as a function of 
added BzIm. The resulting titration curve shows, that at 
least for this base, axial ligation can be considered as 
occurring in two essentially independent stepwise bind 
ing processes. Standard analysis of the data at both 
very low and very high conversion gave values of 
K=1.8-0.2x10 and K2 = 13-3. 
Just as was the case for BzIn, addition of pyridine to 
the five coordinate complex 34.NO3 gave rise to easily 
detected and well-defined changes in the chemical shift 
of the "meso' signals (FIG. 15). In marked contrast to 
the results obtained with BzIn, however, ligation in this 
case cannot be considered to be occurring in a discrete 
stepwise manner. This is quite apparent from an inspec 
tion of FIG. 13 in which the changes in chemical shift 




formed using a Finnigan-MAT TSQ-70 instrument and 
3-nitrobenzyl alcohol as the matrix. Elementary analy 
ses were performed by Galbraith Laboratories. X-ray 
structures were solved as described below and in refer 
ences 11 and 14. 
All solvents and reagents were of reagent grade qual 
ity, purchased commercially, and used without further 
purification. Sigma lipophilic Sephadex (LH-20-100) 
and Merck type 60 (230-400 mesh) silica gel were used 
for column chromatography. The sp3 form of the ligand 
(14) was prepared in 290% yield using the acid cata 
lyzed method described earlier. The currently higher 
yield does not derive from a fundamental change in 
procedure but simply reflects a greater experience with 
this particular key reaction. 
Preparation of 4,5,9,24-tetraethyl-10, 23-dimethyl 
13,20,25,26,27-pentaazapentacyclo 
20.2.1.13.60.18,110.014,19) heptacosa-1,3,5,7,9,11(27), 
12,14,16,18,20,22(25),23-tridecaene, free-base texaphy 
rin' 24. Macrocycle 141 (50 mg, 0.1 mmol) was stirred 
in methanol/chloroform (150 ml, w/v. 2/1) in the pres 
ence of N,N,N',N'-tetramethyl-1,8-diaminonaphthalene 
("proton sponge') for one day at room temperature. 
The reaction mixture was then poured into ice water. 
The organic layer was separated and washed with aque 
ous ammonium chloride solution and then brine. Fol 
lowing concentrations on a rotary evaporator, the 
crude material was purified by chromatography on 
SEPHADEX using first pure chloroform and then 
chloroform/methanol (v/v/ 10/1) as eluents. After 
several faster red bands were discarded, a dark green 
band was collected, concentrated in vacuo, and recrys 
tallized from chloroform/n-hexane to give the sp2 form 
of the ligand as a dark green powder in yields ranging 
from 3-12% with the better yields only being obtained 
on rare occasions. For 24: 1H-NMR (CDCl3) 8=0.90 
(1H, bris, NH), 1.6-1.8 (12H, m, CH2CH3), 3.05 (6H, s, 
CH3), 3.42-3.58 (8H, m, CH2CH3), 8.25 (2H, m, phen. 
CH), 9.21 (2H, s, CH=N, 9.45 (2H, m, phen. CH), 11.25 
(2H, s, CH=C); C.I. MS (CH4) 491 (calcd for 
C32H35N5.H+: 490); FAB MS (3-nitrobenzyl alcohol 
matrix, 8 keV acceleration): m?e 512 (calcd for 
C32H34NsNa+: 512); IR (KBr) v=3420, 2960, 2920, 
2860, 1600, 1560, 1540, 1370, 1350, 1255, 1210, 1080, 
1050, 980, 940, 905, 750 cm-l; UV/VIS (CHCl3) An 
nm (e) 327.0 (30,700); 422.5 (60,500); 692.0 (10,100); 
752.0 (36,400). 
Attempts at binding cadmium with ligand 24 were 
conducted. Several milligrams of compound 24 were 
stirred with an excess of cadmium chloride in chloro 
form/methanol as per the direct insertion methods out 
lined above. Even after 2 days, however, UV/VIS 
(monitoring the Q-type band at 751), indicated that little 
or no metal insertion had taken place. Due to the diffi 
culty of preparing compound or ligand 24 and the obvi 
ous success of the direct insertion procedures described 
herein, no attempts were made to examine other metal 
lation methods. 
The preparation of complex 34.Cl was as follows. 
The sp3 form of the ligand (14); 1 (40 mg, 0.08 mmol) 
was stirred with cadmium chloride (21.4 mg, 0.08 
mmol) in chloroform/methanol (150 ml, w/v 2/1) for 1 
day. The dark green reaction mixture was concentrated 
under reduced pressure on a rotary evaporator and 
chromatographed through silica gel using first pure 
chloroform and then chloroform/methanol (v/v 10/1) 
as eluents. After discarding several leading red bands, 












in vacuo to give compound 34.Cl. This material was 
recrystallized from chloroform/n-hexane to give ana 
lytical pure compound 34Cl as a dark green powder in 
24% yield. For 3Cl: H-NMR (CDCl3) 8=1.55-1.67 
(12H m, CH2CH3)3.03 (6Hs, CH3), 3.04-3.55 (8H, m, 
CH2H3), 8.27 (2H, m, phen. CH), 9.23 (2H, s, CH=N), 
9.40 (2H, m, phen. CH), 11.30 (2H, s, CH=C); 13C 
NMR (CDCl3) 8=9.8, 17.3, 18.1, 19.1, 19.2, 117.6, 
117.8, 128.4, 132.7, 138.2, 139.3, 145.4, 146.7, 150.5, 
153.5, 155.0; FAB MS (3-nitrobenzyl alcohol matrix, 8 
keV acceleration): m/e 602 (114Cd, M+, 100), 601 
(113Cd, M+, 64), 600 (112Cd, M+, 84); IR (KBr) 
v=2950,2910, 2855, 1635, 1605, 1380, 1255, 1210, 1090, 
1010, 795 cm-l; UV/VIS A nm (e) 327.0 (32,800); 
424.0 (72,700); 704.5 (11,000); 767.5 (41,200); anal. calcd 
for C32H3NsCdCl.(..H2O): C, 59.54; H, 5.46; N, 10.85. 
Found: C, 59.78; H, 5.32; N, 10.80. 
The preparation of complex 34.NO3 was as follows. 
The sp3 form of the ligand (14)14 (40 mg, 0.08 mmol) 
was stirred with cadmium nitrate tetrahydrate (31 mg, 
0.1 mmol) in chloroform/methanol (150 ml, w/v = ) for 
1 day. The dark green reaction mixture was then con 
centrated and purified by chromatography on silica gel 
as described above. The resulting crude material was 
then recrystallized from chloroform/n-hexane to give 
analytical pure 3.NO3 in 27% yield.45 For 3.NO3: 1H 
NMR (CDCl3): 6= 1.55-1.70 (12H, m, CH2CH3), 3.04 
(6H, s, CH3), 3.42-3.55 (8H, m, CH2CH3), 8.27 (2H, m, 
phen. CH), 9.20 (2H, S, CH=N), 9.30 (2H, m, Phen. 
CH), 11.07 (2H, s, CH=C); FAB MS (3-nitrobenzyl 
alcohol matrix, 8 KeV acceleration): m/e 602 (114Cd, 
M+, 100), 601 (113Cd, M+, 61), 600 (112Cd, M+,87): IR 
(KBr) v=2960,2920, 2860, 1600, 1550, 1440, 1375, 1200, 
1130, 1075, 1040, 975, 930, 900, 740 cm-l; UV/Vis 
Ana nm (e)=328.0 (39,900), 425.0 (82,800), 706.0 
(14,400), 770 (49,800); Anal. calcd for 
C32H34N5Cd.NO3 (H2O): C, 57.19; H, 5.25; N, 12.50. 
Found: C, 57.12; H, 5.19; N, 11.80. 
Attempts to demetallate complex 34.NO3 were made. 
In an effort to obtain the free sp2 bridged ligand 24, the 
above complex in chloroform was stirred for several 
hours in the presence of sodium sulfide and indepen 
dently with sodium thiosulfate. No significant changes 
in optical properties were observed. Although this did 
not rule out the possibility that changes in axial ligation 
might be taking place, these observations provided rea 
sonable evidence that little or no demetallation occurs 
under the reaction conditions. In the case of sodium 
sulfide, this critical conclusion was further supported by 
FABMS: Other than the starting cationic complex 34, 
no evidence was obtained for any moderate to high 
molecular weight volatile products in the mass spec 
trum. When subject to treatment with aqueous acid, 
complex 34.NO3 appears to undergo hydrolysis (at the 
imine residues) and hence demetallation. The rate of 
this process, however, is strongly pH dependent, the 
half-life being, for instance, on the order of several 
hours in the presence of ca. 0.1N HCl. 
Preparation and isolation of complex 4ba.NO3. The 
sp form of the ligand (14) (40 mg, 0.08 mmol) was 
stirred with cadmium nitrate tetrahydrate (31 mg, 0.1 
mmol) in chloroform/methanol (150 ml, w/v = ) for 1 
day. The dark green reaction mixture was concentrated 
on a rotary evaporator and chromatographed through 
Sephadex using first neat chloroform and then chloro 
form/methanol (v/v 10/1) as eluents. After discarding 
several leading red bands, the dark green band was 
collected and concentrated to give a dark green solid. 
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This was recrystallized from chloroform/n-hexane to 
give a mixture of crystalline and noncrystalline solids in 
27% yield. For this bulk material: H-NMR (CDCl3): 
8=1.55-1.72 (12H, m, CH2CH3), 3.04 (6H, s, CH3), 
3.45-3.58 (8H, m, CH2H3), 6.4 (ca. 3/5H, br. s, BzIm), 
6.8 (ca. 6/5H, br. s., BzIm), 7.27 (ca. 6/5H, s, BzIm), 
829 (2H, m, phen. CH), 9.21 (2H, s, CH=N), 9.32 (2H, 
m, phen. CH), 11.08 (2H, s, CH=C); FABMS (3-nitro 
benzyl alcohol matrix, 8 keV acceleration): m/e 602 
(114Cd, M+, 100), 601 (13Cd, M+,67), 600 (112Cd, M+, 
78); IR (KBr) v=2970, 2935, 2875, 1560, 1382, 1356, 
1300, 1258, 1212, 1085, 1050, 985,910, 755 cm-l; uv/vis 
Ana nm (e) 325.0 (29,000); 425.0 (64,400); 710.5 (9,800); 
767.5 (38,500); anal. Found: C, 42.42; H, 4.28; N, 10.34 
(calcd for C32H3NsCd.NO3(H2O): C, 57.19; H, 5.25; 
N, 12.50; calcd for C32H3NsCd.NO3.BzIm.CHCl3: C, 
53.35; H, 4.59; N, 12.44; calcd for 
C32H3NsCd.NO3. CHCl3: C, 41.26; H, 3.66; N, 8.25). 
The single crystal of 4ba used for the X-ray structure 
determination was isolated from residual noncrystalline 
material following a second recrystallization which 
involved layering a concentrated solution of the above 
crude material in CDCl3 with n-hexane and letting stand 
for several months in the refrigerator. 
Preparation of complex 5a.A.NO3. In a fashion similar 
to that used to prepare the crude cadmium-containing 
complex described above, the sp3 form of the ligand (14) 
was treated with cadmium nitrate tetrahydrate and 
purified on Sephadex. To a ca. 0.7 ml, 0.005M sample of 
this product in CDCl3, was added 25 ul of pyr-D5. The 
resulting solution was layered with n-hexane, and 
placed in the refrigerator. After several months, green 
crystals were isolated in nearly quantitative yield. The 
molecular composition of these crystals was deter 
mined, on the basis of the single crystal X-ray diffrac 
tion analysis reported earlier,11 to be 5a.NO3. CHCl3. H 
NMR (CDCl3/pyr-D5) 6= 1.55-1.70 (12H, m, 
CH2CH3), 3.22 (3H, s, CH3), 3.45-3.56 (8H, m, 
CH2CH3), 8.40 (2H, m, phen. CH), 9.32 (2H, s, 
CH=N),9.75 (2H, m, phen. CH), 11.62 (2H, s, CH=C); 
UV/VIS (CHCl3-pyr v/v 10/1) Ana nm (e) 321.5 
(45,000), 426.5 (79,000), 700.5 (13,500), 765.5 (51,900). 
The 1H NMR titration of 34.NO3 with BzIm or pyr 
D5 was done. Rigorously purified complex 34.NO3 was 
dried at 80° C. under reduced pressure (1 mmHg) for 1 
day. Starting samples for titration were then prepared 
by dissolving this five coordinate complex (3.32 mg, 
0.005 mmol) in 0.7 to 0.75 ml of CDCl3 and transferring 
quantitatively to an NMR tube. To such samples were 
then added increasing aliquots of either BzIm or pyr 
D5 (as solutions of known concentration in CDCl3) and 
recording the chemical shift of the "meso" protons at 
27 C. Control experiments were also carried out by 
adding known quantities of CF3CO2H, D2O, and 
NH4NO3 to similar stock solutions of 3.NO3. In these 
various 1H NMR titrations the absolute chemical shifts 
for any given base to ligand ratio were found to vary by 
less than 0.05 ppm between independent runs, with the 
values of 8-6, the critical observable used for the Ke. 
determinations (see below), being found to vary even 
less (generally so.003 ppm). 
Determination of Binding Constants. Inspection of 
FIGS. 14 and 15 shows that the binding of BzIm to 
cation 3Amay be considered as two well-separated equi 
librium processes. The chemical shift data obtained for 
the "meso" signals as a function of added BzIm were 
thus analyzed as such at both very low and very high 













plots38 were constructed by plotting (6-8)/BzIm) vs 
(6-8) according to equation 4 (which corresponds to 
eq. 5.13 of ref. 38), obtaining K as the absolute value of 
the slope and the term (6-5)K as the intercept. 
(6-8)/Bzins - K(6-5)--(6-6)K (4) 
Here 6 is the observed chemical shift, 5 is the initial 
chemical shift of the pure five or six coordinate starting 
complex (34.NO3 or 4b.NO3), 6 the chemical shift 
calculated for the final mono- or bisligated complexes 
4b.A.NO3 or 5aNO3, K the equilibrium constant in 
question, and BzIm the concentration of free, uncom 
plexed benzimidazole. In both the low and high conver 
sion regimes, it proved necessary to correct for bound 
benzimidazole so as to obtain valid expressions for 
BzIm) in terms of added benzimidazole (BzIm). This 
was done in a straightforward manner according to the 
expressions given in equations 5 and 6, where liglo 
represents the concentration of the starting five coordi 
nate ligand 34.NO3. 
BzIn=BzIno-lig(6-5)/8-5) at low 
Bz.In (5) 
BzInsBzImo-lig at high Bz.In (6) 
Using these corrected values for BzIm), straight line 
Scatchard plots were obtained with R20.99 and 0.98 
respectively for the low and high BzIm) regimes giv 
ing values of K1 and K2 of 1.80x10'M-1 and 12.9M-1 
respectively (see supplementary material). The value 
for K1 is considered to be quite reliable (estimated error 
is 15%); the low solubility of BzIm and the resulting 
incomplete nature of the titration associated with the 
formation of 5a.NO3, however, makes the value ob 
tained for K2 somewhat more approximate (estimated 
error s25%).49 
The changes in "meso' proton chemical shift as a 
function of added pyr shown in FIG, 16 indicate a 
clear absence of two distinct binding regimes. More 
over, as expected, attempts to fit the data as a simple 
monoligation process (to give 6CN material) according 
to eq. 1 did not work. It therefore proved necessary to 
analyze the data in terms of two concurrent equilibrium 
processes. This was done using the convenient iterative 
procedure outlined by Connors. Here the equations of 
interest, corresponding to eqs. 4.31 and 4.32 of Con 
nors,88 as adopted for NMR analyses, are: 
where 8 is the observed Chemical shift, 6 is the initial 
chemical shift of the pure five coordinate starting com 
plex 3.NO3, A11 is the total chemical shift difference 
corresponding to the formation of the pure putative 
monoligated six coordinate species, A12 is the total 
chemical shift corresponding to the formation of the 
bisligated cationic species 5a from the initial five coordi 
nate material, and pyr) is the free pyridine concentra 
tion. A precise expression for pyr) is given by equation 
9,38 where pyro is the concentration total added pyri 
dine, and liglo represents the concentration of the start 
ing five coordinate ligand 34.NO3. 
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(EE Fig.(pyr)+2K1K2(pyr)/(1+K1. to the disorder, the chloroform H atom position was not pyr--KKpyr) calculated. Sw(|Fal-|F-D2 minimized, where 
Inspection of the binding isotherm (FIG. 16), however, 
Suggested that the approximation pyrspyro would be 
reasonably valid over much of the titration range. Initial 
iterative solutions of eqs. 7 (plotting 1/pyr-K1A11/- 
(6-6) vs. pyral2/6-8)-1), giving KK2 and -K1 
as the slope and intercept respectively) and 8 (plotting 
(6-5) {1+K1(pyr)+KK2(pyr)/(pyr) vs. pyr), giv 
ing KK24.12 and K1A11 as the slope and intercept re 
spectively) were therefore made using this greatly sim 
plifying assumption. They converged quickly to give 
initial, uncorrected values of K = 1.5M-1 and 
KK2=308M-2. These values confirmed that under the 
conditions of the experiment (where 34 
NO3)=0.005M), the approximation pyre-pyro is 
valid to within S4% in the regime of greatest interest, 
namely 3<pyridine/ligand)C10 and 0.005M in 34 
NO3. When corrections are made for this small percent 
age, final values of K1 of sl.6M-1 and KK2=315M-2 
are obtained (see supplementary material). We consider 
it important to stress that although the value of K1K2 is 
well determined (estimated error S10%), the nature of 
the data does not allow K1 (and hence K2) to be defined 
with precision (estimated errors.50%). This uncer 
tainty, however, does not detract from the central con 
clusions described herein. 
X-ray Experimental for complex 4ba. For 4b.NO3 
..CHCl3: C40H41N3O3Cl3Cd, M=900.57. The data crys 
tal was a very dark green plate of dimensions 
0.06X0.22X0.44 mm, which was grown by slow diffu 
sion from CHCl3-hexanes and separated from the ac 
companying noncrystalline material as described above. 
The data were collected on a Nicolet R3 diffractometer, 
with a graphite monochromator, using Mo Ka radia 
tion (N=0.71069 A) and a Nicolet LT-2 low-tempera 
ture delivery system (163 K). Lattice parameters were 
obtained from least-squares refinement of 26 reflections 
with 19.2 <28<24.4. The space group was triclinic, 
Pl (No. 2), with Z=2, F(000)=920, as 11.276(4), 
b= 12.845(3), c = 14.913(4) A, a = 84.82(2), 6=69.57(2), 
A=85.84(2), v=2014(1) A, pe=1.48 g-cm-3. Data 
were collected using the omega scan technique (7191 
reflections, 6566 unique, Rint=0.064), 20 range 
4.0-50.0", 1.2 c) scan at 3-6/min. (h=0-14, k=-15, 
1 = - 18->18). Four reflections (-2,2,0; 3,2,3; 
2, -3, -1; - 1,0,-4) were remeasured every 146 reflec 
tions to monitor instrument and crystal stability. Decay 
correction range on I was 0.9863-1.076. Data also cor 
rected for Lp effects and absorption (based on crystal 
shape; transmission factor range 0.8533-0.9557, 
L=7.867 cm). Reflections having FC6or (Fo) con 
sidered unobserved (3272 reflections). The structure 
was solved by heavy atom and Fourier methods and 
refined by full-matrix least-squares procedures in blocks 
of 253 and 287 with anisotropic thermal parameters for 
the non-H atoms (except 03A of the disordered NO3 
group and the terminal C atoms of the disordered ethyl 
groups of one pyrrole ring, C29 site occupancy factor 
0.44(2)), C29A, C31 site occupancy factor 0.37(2) and 
C31A). Nitrate disordered about two orientations of the 
Natom (N1B) with site occupancy factors for the minor 
orientation (0 atoms labeled with A) of 0.45(2). H atoms 
were calculated and refined with isotropic thermal pa 
rameters riding on the relevant C atom. CHCL3 solvent 
is disordered by rotation about a C-Cl bonding axis 
(ClC-C11) with site occupancy factor for the minor 










w=1/(or(F))2+0.0118(F2) and or(F)=0.5kI-(v(I)). 
Intensity I given by (peak-background)x(scan rate) 
and k is the correction due to Lp effects, absorption and 
decay. Sigma(I) estimated from counting statistics; 
or(I)=(peak background)x(scan rate). Final 
R=0.0781 for 3294 reflections, wr=0.114 (Ralps 0.143, 
wRail=0.176) and a goodness of fit=1.00. Maximum 
A/or (0.1 in the final refinement cycle and the mini 
mum and maximum peaks in the final AF map were 
-0.97 and 1.69 e-/A, respectively (in the region of 
the Cd atom). Data reduction, structure solution and 
initial refinement were accomplished using Nicolet's 
SHELXTL-PLUS50software package. The final refine 
ment was done using SHELX76.5 Neutral atom scat 
tering factors for the non-H atoms from Cromer and 
Mann, with anomalous-dispersion corrections from 
Cromer and Liberman,8while scattering factors for the 
H atoms from Stewart, Davidson and Simpson;'''linear 
absorption coefficient from the International Tables for 
X-ray Crystallography (1974). The least-squares 
planes program was supplied by Cordes;56 other com 
pute, programs from reference 11 of Gadol and Da 
vis.57 
Table 1 shows sectional coordinate or equivalent 
isotropic thermal parameters (A) for non-hydrogen 
atoms of 4b.4CHCl3. Table 2 shows bond lengths (A) 
and angles () for non-hydrogen atoms of cation 4ba. 
TABLE 1. Fractional coordinates and isotropic or 
equivalent isotroptic thermal parameters (A2) for non 
hydrogen atoms of 4b.NO3. CHCl3. 
Aton x y 2. U 
Cod .37392(8) .1241(6) .04542(7) .0573(4) 
N1 .5259(9) .1813(7) .1140(9) .065(5) 
C2 5321 (13) .1503(10) 2032(11) .062(6) 
C3 .6213(12) 2115(11) .2219(10) .064(6) 
C4 .666 (11) .278309) .1439(11) .061(6) 
C5 .6066(12) 2575(9) .0765(11) .060(6) 
C6 .6340(12) .3124(9) - 0.106(12) .065(7) 
C7 .5828(11 .3039(8) -.0848(11) .063(6) 
N8 4929(9) 2314(7) -.0754(8) .056(4) 
C9 4750(12) .2437(10) -.1581 (11) .070(6) 
C10 .5492(14) .3233(11) -.2225(10) .075(6) 
C11 .6178(12) .3604(9) -. 1782(1) .069(6) 
Cl2 .3827(14) .1784(12) -.1763(10) .073(6) 
N3 .3236(10) .1169(8) -.1068(8) .057(4) 
C4 .2359011) .0438(11) -.1074(10) .063(6) 
C15 .1851(13) 0468(12) -.1834(10) .072(6) 
C16 .1028(14) -.0250(12) -.1825(10) 067(6) 
C17 .0648(13) -.0982(12) -.1067(11) 071(7) 
C18 .1077(12) -.1040(9) -0331(11) .074(7) 
C9 .1952(12) -.0304(8) -.0304(11) .064(6) 
N20 .2428(10) -0258(9) .04.20(9) .065(5) 
C21 .2112(13) -0873(9) .1201(11) .065(6) 
C22 .2643(12) -0711(9) .1918(11) .065(7) 
N23 .3510(10) .0013(6) .1716(9) .061(5) 
C24 .3782(14) .0029(10) .2535(13) .076(7) 
C25 .3076(14) -0727(10) .3260(12) .080(T) 
C26 .2349(15) -.1183(9) 2854(1) .073(7) 
C27 4669(13) .0715(10) .2649(11) 067(6) 
C28 .6508(14) .2018(13) .3139(11) .084(7) 
C29 .553(5) .234(4) 400(3) .105(15) 
C29A .590(3) .28202) .381(2) .082(8) 
C30 .765(2) .3611 (12) .1304(13) .088(8) 
C3A .710(3) 450(2) .194(2) .101(9) 
C31 .704(3) 475(2) .134(2) 040(7) 
C32 .7108(13) 4478(10) - .2122(1) .072(6) 
C33 .6487(14) 5579(11) - . 1933(13) .088(8) 
C34 .553(2) .3512(14) -.3236(10) .096(8) 
C35 .132(2) - . 1983(1) .3305(13) .093(8) 
C36 .305(2) -0887(12) .4286(11) .084(8) 




Atom x y 2 U 
N1A .2036(10) .2375(6) .1132(8) 059(5) 
C2A .1817(13) .3278(11) 060(2) 095(9) 
N3A .0853(13) .3834(8) .1207(14) ... 101 (8) 
CAA .0536(12) .3373(11) 2074(14) .073(7) 
CSA -0.43(2) .3615(13) .300(2) .103(11) 
C6A -0.56(2) 296(2) .378(2) .116(12) 
C7A .0178(15) .1969(15) 3762(10) .089(7) 
C8A .1056(4) .1750(12) .2886(11) 070(7) 
C9A .1212(11) .2418(9) .2079(10) .053(5) 
C11 .3144(6) 4520(4) .5507(4) .129(3) 
C12 .3058(12) .2261 (8) .5862(6) .118(5) 
C3 .1613(13) .3391 (13) 4877(8) .165(8) 
C12A .056(2) .4327(14) .5339(13) .155(10) 
C13A .2064(15) 2450(12) .5529(14) .157(9) 
CC .19803) .357(2) .5834(15) .152(15) 
NB 9690(14) .6403(9) .1553(10) .073(6) 
Ol 985(3) .588(2) .079(2) .072(11) 
O2 943(4) .734(2) .i67(2) .17(2) 
O3 958(3) .587(2) .233(2) .123(14) 
O1A .853(3) .660(4) .199(3) .19(2) 
O2A 1.043(3) 598(3) 089(3) .065(13) 
O3A 1.030(5) .676(4) .173(3) .16(2) 
For Anisotropic atoms, the U value is U calculated as U = xjuga?'a?'Ali 
where A is the dot product of the i" and j" direct space unit cell vectors. 
for non-H atoms of cation 4ba. 
TABLE 2 
Bond Lengths (A) and Angles () 
l 2 3 -2 1-2-3 
C2 N C5 1.38(2) 107.2(13) 
C5 N 1.33(2) 
C3 C2 C27 1.43(2) 124.(2) 
C3 C2 N1 109.5(11) 
C27 C2 N1 1.37(2) 126.3(15) 
C4 C3 C28 1.35(2) 129.3(14) 
C4 C3 C2 105.9(14) 
C28 C3 C2 1.51(2) 124.7(12) 
C5 C4 C30 1.44(3) 126.9(13) 
C5 C4 C3 107.8(12) 
C30 C4 C3 1.55(2) 125.(2) 
C6 C5 N 1.37(2) 129.(2) 
C6 C5 C4 121.7(12) 
N1 C5 C4 109.5(13) 
C7 C6 C5 1.43(3) 129.2(12) 
N8 C7 C11 1.39(2) 110.7(14) 
N8 C7 C6 121.3(12) 
C1 C7 C6 1.45(2) 127.8(12) 
C9 N8 C7 1.31(2) 103.3(11) 
C10 C9 Cl2 1.43(2) 127.(2) 
C10 C9 N8 113.6(14) 
Cl2 C9 N8 1.49(2) 119.7(11) 
C1 C10 C34 1.32(2) 127.8(13) 
C11 C10 C9 106.7(14) 
C34 C10 C9 1.51(2) 125.(2) 
C32 C11 C7 1.52(2) 125.(2) 
C32 C C10 129.1 (15) 
C7 C CO 105.7(11) 
N13 C2 C9 1.26(2) 115.2(15) 
C14 N13 Cl2 1.41(2) 126.1 (14) 
C15 Cl4 C19 1.43(2) 119.5(13) 
C15 C4 N13 121.7(12) 
C19 C14 N3 1.39(2) 118.7(14) 
C16 C5 C14 1.25(2) 120.2(13) 
C17 Cl6 C15 1.37(2) 119.(2) 
C18 C17 Cl6 1.34(3) 123.(2) 
C19 C8 C17 1.43(2) 1200(13) 
N20 C19 C14 1.37(2) 116.6(12) 
N20 C19 C18 125,7(12) 
C14 C19. C18 i 18,(2) 
C2 N20 C19 1.30(2) 124.2(13 
C22 C2 N20 1.43(3) 18.3(13) 
N23 C22 C26 1.34(2) 113.(2) 
N23 C22 C2 118.0(13) 
C26 C22 C2 i.41(2) 129.1 (12) 
C24 N23 C22 1.36(2) 104.7(12) 
C25 C24 C27 1.44(2) 125.(2) 
C25 C24 N23 111.1 (14) 













Bond Lengths (A) and Angles () 
for non-H atoms of cation 4ba. 
1 2 3 1-2 1-2-3 
C26 C25 C36 1.37(3) 127.9(13) 
C26 C25 C24 105.(2) 
C36 C25 C24 1.52(3) 127.02) 
C35 C26 C22 1.54(2) 124.(2) 
C35 C26 C25 129.(2) 
C22 C26 C25 106.3(12) 
C2 C27 C24 130.02) 
C29 C28 C3 1.44(4) 118.03) 
C29A C28 C3 1.46(3) 115.(2) 
C3A C30 CA 1.51(3) 112.(2) 
C31 C30 CA 1.57(3) 111.(2) 
C33 C32 C1 1.54(2) 114.0(11) 
C37 C36 C25 1.47(2) 114.(2) 
C9A N1A C2A 1.40(2) 108.5(10) 
C2A NA 1.40(2) 
N3A C2A NA 1.35(2) 107.(2) 
CAA N3A C2A 1.31(3) 109.4(14) 
C5A CAA C9A 1.47(3) 115.(2) 
C5A CAA N3A 133.3(14) 
C9A C4A N3A 1.40(2) 111.2(13) 
C6A CSA CAA 1.34(3) 120.02) 
C7A C6A C5A 1.47(3) 124.(2) 
C8A CA C6A 1.37(2) 115.(2) 
C9A C8A C7A 1.38(2) 121.7(4) 
NA C9A CaA 103.7(12) 
N1A C9A C8A 132.1(11) 
C4A C9A C8A 124.1(3) 
The characterization by X-ray diffraction analysis of 
a six coordinate pentagonal pyramidal cadmium(II) 
cationic complex 4bA derived from a novel aromatic 22 
T-electron pentadentate "expanded porphyrin' ligand 
(24) is described. The X-ray structure reveals the five 
central donor atoms of the macrocycle to be coordi 
nated to the cadmium(II) cation which in turn lies 
0.334(2) A above the mean plane of the macrocyle and 
is further ligated by an apical benzimidazole ligand. As 
is true in the corresponding pentagonal bipyramidal 
bispyridine adduct 5aa, the X-ray structure of cation 
4bA indicates the macrocyclic ligand to be nearly planar 
(maximum deviation 0.154(13) A for C15) with the five 
donor nitrogen atoms defining a near circular cavity 
with a center-to-nitrogen radius of =2.42 A. The crys 
tals of 4bA.NO3 used for the X-ray diffraction analysis 
were isolated from an inhomogeneous mixture of crys 
talline and noncrystalline material obtained following 
treatment of the sp3 form of the ligand (14) with 
Cd(NO3)2.(H2O)4 and subsequent purification on sepha 
dex. The proton NMR spectrum in CDCl3 of this bulk 
material is essentially identical to that of the pure five 
coordinate complex 34 prepared independently, but 
showed the presence of a broad feature at ca. 6.4 ppm 
and two sharper peaks at 6.81 and 7.27 ppm ascribable 
to the bound benzimidazole ligand. These diagnostic 
ligand features are reproduced upon titrating the pure 
five coordinate complex 34 with roughly 3/5 equivalent 
of benzimidazole. This finding suggests that the bulk 
material from which crystals of 4bA.NO3 were isolated 
consists of a mixture of crystalline and noncrystalline six 
and five coordinate species and supports the hypothesis 
that the bound benzimidazole found in cation 4b is 
derived from degradative side reactions associated with 
the metal insertion and accompanying ligand oxidation. 
From these titrations the values for the sequential for 
mation constants (K1 and K2) for the binding of the first 
and second equivalents of benzinidazole to the five 
coordinate cationic complex 34 were determined to be 
1.8x10"M-1 respectively. For the complexation of 
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pyridine to 34.NO3, K.K2 values of 1.6M and 
315M respectively were determined from similar H 
NMR titrations. These results indicate that in ben 
Zimidazole-containing chloroform solutions an ex 
tended concentration range exists wherein the pentago 
nal pyramidal complex 4ba is the primary cadmium 
containing species, whereas in the presence of pyridine 
it is either the unligated complex 34 or the coordina 
tively saturated pentagonal bipyramidal species 5a 
which will dominate in solution. 
Published literature references in the following list 
are incorporated by reference herein for the reasons 
cited. 
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EXAMPLE 3 
Gadolinium(III) complexes derived from strongly 
binding anionic ligands, such as diethylenetrianine pen 
taacetic acid (DTPA), 23 1,4,7,10-tetraazacyclododec 
ane N,N',N,",N'-tetraacetic acid (DOTA),145 and 
1,10-diaza-4,7,13,16-tetraoxacyclooctadecane-N,N'-dia 
cetic acid (dacda), 6 are among the most promising of 
the paramagnetic contrast currently being developed 
for use in magnetic resonance imaging (MRI). Indeed, 
GdDTPA) is now undergoing clinical trials in the 
United States for possible use in enhanced tumor detec 
tion protocols. Nonetheless, the synthesis of other 
gadolinium(III) complexes remains of interest since 
such systems might have greater kinetic stability, supe 
rior relaxivity, or better biodistribution properties than 
the existing carboxylate-based contrast agents. One 
approach currently being pursued is based on using 
water-soluble porphyrin derivatives, such as tetrakis(4- 
sulfonatophenyl)porphyrin (TPPS).789 Unfortunately, 
the large gadolinium(III) cation cannot be accommo 
dated completely 10 within the relatively small prophy 
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rin binding core (rs2.0 A11), and, as a consequence, 
gadolinium porphyrin complexes are invariably hydro 
lytically unstable.7812.13 Larger porphyrin-like ligands, 
however, might offer a means of circumventing this 
problem.14-22 
As previously described, the present invention invol 
ves: the synthesis of a novel "expanded porphyrin" 
system, 1B (to which the trivial name "texaphyrin' has 
been assigned'), and the structure of the bispyridine 
adduct of its cadmium(II) complex 2B. See FIG. 17 for 
the structures of compound or complex 1B-11B. The 
presence in this structure of a near circular pentadentate 
binding core which is roughly 20% larger than that of 
the porphyrins, coupled with the realization that al 
most identical ionic radii pertain for hexacoordinate 
Cd2+ (r=0.92 A) and Gd3+ (r=0.94 A).25 prompted 
exploration of the general lanthanide binding properties 
of this new monoanionic porphyrin-like ligand. The 
synthesis and characterization of a water-stable 
gadolinium(III) complex (7) derived formally from a 
new 16,17-dimethyl substituted analogue (6B)26 of the 
original "expanded porphyrin' system, as well as the 
preparation and characterization of the corresponding 
europium(III) and samarium(III) complexes 8b and 9B 
(See FIG. 17). 
Electronic spectra were recorded on a Beckman 
DU-7 spectrophotometer. IR spectra were recorded, as 
KBr pellets, from 4000 cm- to 600 cm-lon a Perkin 
Elmer 1320 spectrometer. Low resolution fast atom 
bombardment mass spectrometry (FABMS) was per 
formed at Austin using a Finnigan-MATTSQ-70 instru 
ment and either 3-nitrobenzyl alcohol or glycerol/ox 
alic acid as the matrix; high resolution FABMS analy 
ses (HRMS) were performed at the Midwest Center for 
Mass Spectrometry using CsI as a standard. Elementary 
analyses were performed by Galbraith Laboratories. 
Materials. All solvents and reagents were of reagent 
grade quality, purchased commercially, and used with 
out further purification. Sigma lipophilic SEPHADEX 
(LH-20-100) and Merck type 60 (230–400 mesh) silica 
gel were used for column chromatography. 
Preparation of Nd complex 3B. The sp3 form of the 
ligand 1027 (50 mg, 0.1 mmol) was stirred with neodym 
ium nitrate pentahydrate (63 mg, 0.15 mmol) and proton 
sponge (64 mg, 0.3 mmol) in chloroform/methanol (150 
ml, w/v) for one day. The dark green reaction mixture 
was poured onto ice/water/ammonium chloride and 
extracted with chloroform. The organic layer was 
washed with aqueous ammonium chloride and concen 
trated under reduced pressure. The complex was chro 
matographed through sephadex using neat chloroform, 
chloroform/methanol (10:1), methanol, and water. The 
dark green band collected from methanol was concen 
trated and recrystallized from chloroform/methanol/n- 
hexane (ratio of chloroform to methanol is 1 to 2) to 
yield 13 mg of 3 (18%). For 3: UV/VIS (CH3OH) *n. 
(e): 330.5 (33,096), 432.5 (85,762), 710.5 (10,724), 774.5 
(38,668); FAB MS (glycerol matrix); m/e (relative in 
tensity) 631 (142Nd,95), 633 (144Nd, 100), 635 (146Nd, 
77); IR (KBr) * 3360,2965,2930, 2870, 1610, 1560, 1450, 
1400, 1350, 1250, 1205, 1135, 1080, 1050, 980, 940, 905, 
755 cm-l. 
The preparation of Sm complex 4B was as follows. 
The macrocyle 10B27 (40 mg, 0.08 mmol) was stirred 
with platinum oxide (18 mg. 0.08 mmol) and sanarium 
acetate hydrate (69 mg, 0.2 mmol) under reflux in ben 
zene/methanol (50 ml, w/v., 1/1). After two hours the 
reaction mixture was filtered through celite and concen 












purified by chromatography through Sephadex using 
only chloroform as an eluent. After discarding a red 
band, a green band was collected, concentrated in 
vacuo, and recrystallized from chloroform/n-hexane to 
give 0.8 mg of 4 (ca.1%). For B: UV/VIS manm 438, 
706.5, 769; FAB MS (3-nitrobenzyl alcohol matrix): 
m/e (relative intensity) 635 (147Sm,78), 636 (149Sm, 72), 
637 (149Sm, 73), 640 (152Sm, 100), 642 (154Sm, 55). 
The preparation of Eu complex 5B was as follows. 
The macrocycle 1027 (50 mg, 0.1 mmol) was stirred with 
europium acetate hydrate (34 mg, 0.1 mmol) and proton 
sponge (64 mg, 0.3 mmol) in chloroform/methanol (150 
ml, w/v, ) for one day. The reaction mixture was 
poured onto ice/water and extracted with chloroform. 
The organic layer was washed with aqueous ammonium 
chloride then concentrated and recrystallized from 
chloroform/n-hexane. The recrystallized solid was pu 
rified by column chromatography through sephadex 
using neat chloroform and neat methanol as eluents. 
The dark green band collected in methanol was concen 
trated to yield a small amount of a dark green solid 
(<1%). For 5: UV/VIS "a nm 438, 700, 765; FAB 
MS (3-nitrobenzyl alcohol matrix); m/e (relative inten 
sity) 639 (151Eu, 94), 641 (153Eu, 100). 4,5,9,24-Tetraeth 
yl-10,16,1723-tetramethyl-13,20,25,26,27-pentaazapen 
tacyclo[20.2.1.13.60.18,110.014, 19heptacosa 
3,5,8,10,12,14(19), 15, 17,2022,24-undecene (11B). This 
macrocycle was prepared in ca. 90% yield from 1,2- 
diamino-3,4-dimethylbenzene and 2,5-bis-(3-ethyl-5-for 
myl-4-methylpyrrol-2-ylmethyl)-3,4-diethylpyrrole 
using the acid catalyzed procedure reported earlier for 
the preparation of 10B27 For 11: mp 200 -C dec; 1H 
NMR 3 1.06 (6H, t, CH2CH3), 1.13 (6H, t, CH2CH3) 
2.15 (6H, s, phenyl-CH3), 2.22 (6 H, s, pyrrole-CH3), 
2.38 (4H, q, CH2CH3), 2.50 (4H, q, CH2CH3), 3.96 (4 
H, s, pyrrole2-CH2), 7.19 (2 H, s, aromatic), 8.10 (2H, s, 
CHN), 11.12(1H, s, NH), 12.48 (2H, s, NH); 13C NMR 
89.49, 15.33, 16.47, 17.22, 17.71, 19.52, 22.41, 117.84, 
120.40, 120.75, 125.11, 125.57, 134.95, 135.91, 141.63; 
UV/VIS .367 mm; FABMS, M+ 522; HRMS, M+ 
521.35045 (calc. for C4H43Ns 521.35185). 
Preparation of Gd complex 7B. The sp3 form of ligand 
11 (42 mg, 0.08 mmol) was stirred with gadolinium 
acetate tetrahydrate (122 mg, 0.3 mmol) and proton 
sponge (54 mg, 0.25 mmol) in chloroform/methanol 
(150 ml, v/v ) for one day. The dark green reaction 
mixture was concentrated under reduced pressure and 
chromatographed through silica gel (25 cm.X.5 cm.) 
which was pretreated with chloroform/triethylamine 
(50 ml, v/v 25/1). Chloroform/triethylamine (25/1) and 
chloroform/methanol/triethylamine 25/2.5/1 v/v) was 
used as eluents. A dark red band was first collected 
followed by two green bands. The last green band, 
which showed a clear aromatic pattern by UV/VIS, 
was concentrated and recrystallized from chloro 
form/n-hexane to give 14 mg (22%) of the Gd complex 
7B. For 7B: FAB MS (methanol/oxalic acid/glycerol 
matrix): m/e (relative intensity) 671 (155Gd, 58), 672 
(156Gd, 78), 673 (157Gd, 94), 674 (158Gd, 100), 676 
(160Gd, 64); HRMS, M+ 674.2366 (calcd. for 
C3H3Ns 158Gd 674.2368): UV/VIS (CHCl3) *, nm 
(e) 339.5 (14,850), 450.5 (36,350), 694.5 (6,757), 758.0 
(23,767); IR (KBr) * 2990, 2960,2900, 2830, 2765,2700, 
2620, 2515, 1710, 1550, 1440, 1410, 1395, 1365, 1265, 
1220, 1180, 1150, 1105, 1090, 1060, 1040, 1095, 1045, 
1015, 680 cm-l; Anal. calc. for C34H38N5Gd'(OH)22 
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H2O: C, 54.89; H, 5.96; N, 9.41. Found: C, 54.49; H, 
5.95; N, 8.97. 
The preparation of Eu complex 8B was carried out. 
The macrocycle 11B (53 mg, 0.1 mmol) was stirred with 
europium acetate hydrate (105 mg, 0.3 mmol) and pro 
ton sponge (64 mg, 0.3 mmol) in chloroform/methanol 
(150 ml, v/v) for 6 hrs. The dark green reaction mix 
ture was concentrated under reduced pressure as de 
scribed above with one exception. Chloroform/trie 
thylamine (25:1) and chloroform/methanol/triethyla 
mine (25:5:1) were used as eluents. The green complex 
8 was recrystallized from chloroform/n-hexane to yield 
26 mg of product (33%). For 8B: UV/VIS (CHCl3) 
'm nm (e) 339.5 (24,570), 450.5 (63,913), 696.0 
(10,527), 759.0 (40,907); FAB MS (methanol/oxalic 
acid/glycerol matrix): m/e (relative intensity) 667 
(151Eu, 79), 669 (153Eu, 100); HRMS, M+, 669.2336 
(calc for C3H38N5153Eu 669.2340); IR (KBr) 2970, 
2930, 2870, 2740, 2680, 2600, 2500, 1700, 1535, 1430, 
1350, 1255, 1205, 1165, 1135, 1095, 1075, 1050, 1030, 
980, 900 cm-l; Anal calc. for C3H38N5Bu(OH)2O: C, 
56.66; H, 5.87; N, 9.72. Found: C, 55.92; H, 5.47; N, 9.95. 
The preparation of the Sm3+ complex 9B was as fol 
lows. The spform of the ligand (11B)(52 mg, 0.1 mmol) 
was stirred with samarium acetate hydrate (103.5 mg, 
0.3 mmol) and proton sponge (64 mg, 0.3 mmol) in 
chloroform/methanol (150 ml, v/v) for one day. The 
dark green reaction mixture was concentrated and puri 
fied by silica gel chromatography as described above. 
The resulting crude material was then recrystallized 
from chloroform/n-hexane to give 29 mg of 9 in 37% 
yield. For 9: UV/VIS (CHCl3) *na nm (e) 339.5 
(21,617), 451.0 (56,350), 695.5 (9,393), 760.0 (35,360); 
FAB MS (3-nitrobenzyl alcohol): m/e (relative inten 
sity) 663 (147Sm, 74.8), 664 (148Sm, 82.3), 665 (149Sm, 
84.58), 668 (152Sm, 100, 670 (154Sm, 78.5); HRMS, M+, 
668.2300 (calc. for C34H38Ns 152Sm 668.2322); IR (KBr) 
* 2990, 2950, 2890, 2760, 2700, 2620, 2520, 1720, 1620, 
1550, 1440, 1360, 1265, 1215, 1145, 1105, 1085, 1060, 
995, 945, 910, 680 cm-l; Anal. calc for 
C34H38Ns.Sm'(OH)2O: C, 54.08; H, 6.14; N, 9.27. 
Found: C, 54.30; H, 5.66; N, 9.06. 
As described earlier,23 (see Example 1) treatment of 
the methylene-bridged, or sp3 form of the texaphyrin 
macrocycle 10B with Cd(II) salts in air saturated me 
thanol/chloroform at ambient temperature leads to the 
formation of the green CdCII) complex 2 in roughly 
25% yield, with both metal insertion and oxidation 
taking place concurrently under the reaction condi 
tions. When a similar procedure was carried out using a 
variety of trivalent lanthanide salts i.e. Ce(OTf)3, 
Pr(OAc)3, Nd(NO3)3, Sm(OAc)3, Eu(OAc)3 
Gd(OAc)3, Dy(OTf)3, TbCl3, Er(OTf)3, Tm(NO3)3, 
and Yb(NO3)3) no metal complexes of 1 (or 10) were 
obtained (as judged by the absence of changes in the 
UV/visible spectrum). If, however, N,N',N',N'-tet 
ramethyl-1,8-diaminonaphthalene ("proton sponge”) 
was added to the various reaction mixtures, the high 
energy, low intensity band of 10 at "max=365 nm disap 
peared over the course of several hours to several days 
(depending on the salt in question) and was replaced by 
two strong transitions in the 435-455 nm (Soret) and 
760-800 nm (Q-band) regions, suggesting that ligand 
oxidation and metal binding had occurred.28 Unfortu 
nately, isolation of these putative metal-containing 
products proved problematic: Direct chromatography 
on either silica gel or lipophilic Sephadex in general 













1B and essentially none of the desired metalated mate 
rial. Indeed, only in the case of the samarium(III) ace 
tate salt did it prove possible to isolate a trace quantity 
(ca.1% yield) of the desired complexes (4) by chroma 
tography on Sephadex. It was interesting to find, how 
ever, that a dark green neodymium(III) complex 3B 
could be obtained in almost 20% yield by quenching the 
reaction mixture with ice water, extracting repeatedly 
with chloroform, washing with aqueous ammonium 
chloride, purifying by chromatography on Sephadex, 
and recrystallizing from chloroform/methanol/n-hex 
ane. Unfortunately this work-up procedure proved inef 
fective in the case or the other putative lanthanide com 
plexes (including, unfortunately, that derived from 
Gd3+), although it did prove possible to obtain trace 
quantities of the europium(III) complex (5B) using this 
procedure. 
Since spectral evidence suggested that metal uptake 
and ligand oxidation were occurring when the spinac 
rocycle 10B was treated with numerous other Ln3+ 
salts, it was puzzling that only the neodymium(III) 
complex (3) could be isolated in reasonable yield. A 
careful analysis suggested that, in certain instances, 
notably Sm3+, Eu3+, Gd3+, the problem was not due 
to hydrolytic instability. Rather, it derived from the 
very high water solubility of the lanthanide complexes 
which precluded reextraction back into organic sol 
vents following the initial aqueous washes! This obser 
vational hypothesis led to the consideration that more 
hydrophobic texaphyrin analogues would prove valu 
able in the preparation and isolation of "expanded por 
phyrin' lanthanide complexes. 
To test the above assumption, a simple dimethylated 
analogue (11B) of the original sphybridized ligand 10B 
was prepared. This new, more hydrophobic, sphybrid 
ized ligand was obtained in ca. 90% yield by condensing 
1,2-diamino-4,5-dimethylbenzene with 2,5-Bis-(3-ethyl 
5-formyl-4-methylpyrrol-2-ylmethyl)-3,4-diethylpyr 
role under acid catalyzed conditions identical to those 
used to prepare 10.27 Treatment of this texaphyrin pre 
cursor with Gd(OAc)3, Eu(OAc)3, and Sm(OAc)3 
under reaction and workup conditions similar to those 
used to obtain 3B, then gave the cationic complexes 7B, 
8B, and 9B, as their dihydroxide adducts,29 in 22%, 33%, 
and 37% yields respectively. It appears that these in 
creased yields derive directly from the increased hydro 
phobicity of the new dimethyl substituted texaphyrin 
ligand system (6B). 
The new lanthanide complexes reported here are 
unique in several ways. For instance, as judged by fast 
atom bombardment mass spectrometric (FAB MS) 
analysis, complexes 38-5B and 7B-9B are mononuclear 
1:1 species, a conclusion that is further supported, in the 
case of compounds 7B-9B, by both high resolution FAB 
MS accurate molecular weight determinations and 
combustion analysis. In other words, we have found no 
evidence of 1:2 metal to ligand "sandwich' systems, or 
higher order combinations as are often found in the case 
of the better studied lanthanide porphyrins.31 
The electronic spectra represents a second remark 
able feature of these new materials: All six lanthanide 
complexes isolated to date display a dominant Soret-like 
transition in the 435-455 nm region which is considera 
bly less intense than that observed in the corresponding 
metalloporphyrins (c.f. FIG. 18), and show a promi 
nent low energy Q-type band in the 760-800 nm region. 
This latter feature is diagnostic of this class of 22 at-elec 
tron "expanded porphyrins' and is both considerably 
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more intense and substantially red-shifted (by ca. 200 
nnn) as compared to the corresponding transitions in 
suitable reference lanthanide prophyrins (e.g., 
Gd'TPPS), 'nais575 nmi). Within the context of 
these general observations, it is interesting to note that 5 
complexes derived from the somewhat more electron 
rich ligand 6B all display Q-type bands that are blue 
shifted by ca. 5-15 nm as compared to those obtained 
from the original texaphyrin 1B. 
A third notable property of complexes 7B-9B is their 
high solubility in both chloroform and methanol. The 
fact that these three complexes are also moderately 
soluble (to roughly 103M concentrations) in 1:1 (v.v.) 
methanol/water mixtures was of particular interest. 
Moreover, as initially suggested on the basis of the 
preliminary studies with 3-5 discussed above, these 
materials are stable to these solvent conditions. For 
instance, a 3.5x 105M solution of the gadolinium com 
plex 7B in 1:1 (v.v.) methanol/water at ambient temper 
ature shows less than 10% bleaching of the Soret and 
Q-type bands when monitored spectroscopically over 
the course of 2 weeks. This suggests that the half-life for 
decomplexation and/or decomposition of this complex 
is 2100 days under these conditions. Under the condi 
tions of the experiment described above, no detectable 
shifts in the position of the Q-type band are observed 
yet the Q-type transition of the free-base 6B falls ca. 20 
nm to the blue of that of 7B,30 while shifts in this direc 
tion would be expected if simple demetalation were the 
dominant pathway leading to the small quantity of ob 
served spectral bleaching. 
The strong hydrolytic stability of complexes 7B-9B is 
in marked contrast to that observed for simple, water 
soluble gadolinium porphyrins, such as GdTPPS)t, 
which undergo water-induced demetalation in the 
course of several days when exposed to an aqueous 
environment." It thus appears likely that gadolinium 
(III) complexes derived from the new texaphyrin ligand 
6B, or its analogues, should provide the basis for devel 
oping new paramagnetic contrast reagents for use in 
MRI applications. In addition, the ease of preparation 
and stable mononuclear nature of complexes 7B-9B sug 
gests that such expanded porphyrin ligands might pro 
vide the basis for extending further the relatively under 
developed coordination chemistry of the lanthanides. 
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EXAMPLE 4 
The photophysical properties of a new series of tri 
pyrroledimethine-derived "expanded porphyrins' 
("texaphyrins') are reported; these compounds show 
strong low energy optical absorptions in the 730-770 
nm spectral range as well as a high triplet quantum 
yield, and act as efficient photosensitizers for the pro 
duction of singlet oxygen in methanol solution. 
Photodynamic therapy is among the more promising 
of modalities currently being considered for the treat 
ment of localized neoplasia and eradication of viral 
contaminants in blood.2 As a result, considerable effort 
has been devoted to the development of effective 
photochemotherapeutic agents. To date, porphyrins 
and their derivatives, phthalocyanines, and naph 
thalocyanines have been among the most widely studied 
compounds in this regard. Unfortunately, all of these 
dyes suffer from critical disadvantages. While porphy 
rin derivatives have high triplet yields and long triplet 
lifetimes (and consequently transfer excitation energy 
efficiently to triplet oxygen),3b38 their absorption in the 
Q-band region often parallels that of heme-containing 
tissues. Phthalocyanines and naphthalocyanines absorb 
in a more convenient spectral range but have signifi 
cantly lower triplet yields; moreover, they tend to be 
quite insoluble in polar protic solvents, and are difficult 
to funtionalize. Thus at present the development of 
more effective photochemotherapeutic agents appears 
to require the synthesis of compounds which absorb in 
the spectral region where living tissues are relatively 
transparent (i.e., 700-1000 nm), ld have high triplet 
quantum yields, and are minimally toxic. The present 
inventors have recently reported (see Example 1) the 
synthesis of a new class of aromatic prophyrin-like mac 
rocycles, the tripyrroledimethine-derived "texaphy 













730-770 nm range. The photophysical properties of 
metallotexaphyrins 1-7 parallel those of the corre 
sponding metallaporphyrins and the diamagnetic com 
plexes 1-4 sensitize the production of O2 in high quan 
tum yield. FIG. 19 shows the schematic structure, metal 
complexes and derivatives of compounds of the present 
invention (1-7). m 
The absorption spectrum of 1'Cl is shown in FIG. 
20. This spectrum, which is representative of this class 
of compounds (cf. Table 3), is characterized by strong 
Soret- and Q-type bands, the latter being of particular 
interest. The fluorescence excitation spectrum of this 
complex, monitored at the emission maximum (ca. 780 
nm; see inset to FIG. 20), and the absorption spectrum 
are superimposable in the visible region (370-800 nm) 
showing that internal conversion to the first excited 
singlet state is quantitative upon photoexcitation in the 
Soret or Q-band regions. While the fluorescence quan 
tum yields (di) for 1-4 are only 0-1%, the quantum 
yields for triplet formation (b) of these diamagnetic 
metalltexaphrins can approach unity and resemble those 
found for metalloporphyrins. The triplet-triplet tran 
sient spectrum of 1. Cl, given in FIG. 21, shows 
bleaching in the Soret- and Q-bands of the ground state 
and a positive absorbance change in the 450-600 nm 
region, again reminiscent of metalloporphyrin triplet 
spectra.7 The inset of FIG. 21 shows the decay of this 
triplet state in deoxygenated methanol, from which a 
lifetime (t) of 67 us is calculated. Similar triplet spec 
tra, lifetimes, and quantum yields were found for other 
diamagnetic metallotexaphyrin derivatives in methanol 
and for 1'C1 in mixed methanol-water solutions. Inter 
estingly, low temperature phosphorescence could not 
be observed for any of the compounds in methanol 
glasses. Finally, several complexes containing paramag 
netic metal ions (e.g. Mn, SmII, and EuIII, structures 
5-7) were investigated. They proved to be non 
luminescent and their triplet excited states could not be 
detected with our laser flash photolysis set-up, which 
has a time resolution of ca. 10 ns. 
In methanol solution, the triplet excited states of 
14 were quenched by molecular oxygen with bi 
omolecular rate constants of (2.6-0.2)x109 dm3 moll 
s-1. In aerated solution, the triplet state decay profile 
could be described in terms of a single exponential pro 
cess with an average lifetime of (17520) ins; thus, inter 
action between the triplet species and O2 is quantitative. 
Laser excitation (355 nm, 80 m, 10 ns) of the compound 
in aerated methanol gave no redox products (e.g. texa 
phyrin cation and superoxide anion) but, using a Ge 
diode, the production of O2 was observed clearly from 
its characteristic luminescence at 1270 nm. This lumi 
nescence decayed with a lifetime of 12.5-0.3 us and its 
initial intensity, as extrapolated to the centre of the laser 
pulse, was a linear function of the number of photons 
absorbed by the texaphyrin complex. Comparison of the 
initial intensity with that obtained using tetrakis (4- 
hydroxyphenyl)porphyrin (THPP) as photosensitizer3b 
under identical conditions allowed calculation of the 
quantum yields for production of singlet oxygen (1.2). 
The derived values are seen to parallel the triplet quan 
tum yields (Table 3); the triplet state reaction appears to 
partition between generation of O2 (74-78%) and for 
mation of vibrationally excited O2 (22-26%). These 
(1.2 values compare favourably with those observed 
with porphyrins and are much superior to values ob 
tained with phthalocyanines and naphthalocyanines 
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due to the improved triplet state yields. Thus diamag 
netic texaphyrin complexes appear to be highly efficient 
photosensitizers for the formation of 102. 
TABLE 3 
Optical and photophysical properties 
of metallotexaphyrins in CH3OH. 
Absorption Emission Dr D t DiO2 
Complex gnar(nm gnar(nm) (10%) (-5%) (ms) (tio%) S() 
iC 410 32 767 0.03 0.82 67 0.61 0.4 
2C 412 38 765 0.012 0.88 37 0.65 0.73 
3NO3 47 759 780 0.011 0.88 55 0.69 0.78 
4NO3 42 760 788 0.009 0.97 36 0.74 0.76 
5OH 420 60 <0.001 ND() - (<0.05 an 
6(OH)2 450 763 <0.00 ND - C0.05 wo 
7OH)2 451 762 a (0.00 ND - CO.05 ow 
SiNC(c) 310 776 780 ra- 0.39 331 0.35 0.90 
(s = / 
(ND = not detected o 
SiNC = bis(tri-n-hexylsiloxy)(2,3-naphthalocyaninato) silicon in benzene; see reference 4. 
2O 
In summary, the new metallotexaphrin complexes 
discussed here show three important optical properties 
which make them unique among existing porphyrin-like 
macrocycles. They absorb strongly in a physiologically 
important region (i.e. 730-770 nm), form long-lived 
triplet states in high yield, and act as efficient photosen 
sitizers for the formation of singlet oxygen (see, e.g. 
FIG. 21). These properties, coupled with their high 
chemical stability and appreciable solubility in polar 
media, suggest that these cationic complexes could 
serve as viable photosensitizers in emerging photody 
namic protocols. Preliminary in vitro studies of 3NO3 
in 10% human serum, in which a significant decrease in 
herpes simplex (HSV-1) infectivity and lymphocyte 
mitogenic activity are observed upon irradiation at 767 
nm,' affirm the feasibility of this approach. 
6. "The Porphyrins'; D. Dolphin, Ed., Academic Press: 
New York, 1978-1979, Vols. I-VII. 
7. A. Harriman, J. Chem. Soc., Faraday Trans. 2, 1981, 
77, 1281. 
8. M. A. J. Rodgers and P. T. Snowden, J. Am. Chem. 
Soc., 1982, 104,5541. 
9. M. H. Judy, J. L. Matthews, G. Hemmi, J. L. Sessler, 
to be published. 
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EXAMPLE 5 
Acquired immunodeficiency syndrome (AIDS) and 
cancer are among the most serious public health prob 
lems facing our nation today. AIDS, first reported in 
1981 as occurring among male homosexuals, is a fatal 
human disease which has now reached pandemic pro 
portions. Cancer, in spite of some very significant ad 
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remains the third leading cause of death in this country. 
Finding better ways to detect, treat, and reduce the 
transmission of these disorders are thus research objec 
tives of the highest importance. 
One of the more promising new modalities currently 
being explored for use in the control and treatment of 
tumors is photodynamic therapy (PDT). 1-5 This tech 
nique is based on the use of a photosensitizing dye, 
which localizes at, or near, the tumor site, and when 
irradiated in the presence of oxygen serves to produce 
cytotoxic materials, such as singlet oxygen (O2(l")), 
from otherwise benign precursors (e.g. (O2(X-)). 
Much of the current excitement associated with PDT 
derives from just this property: In marked contrast to 
current methods (e.g. conventional chemotherapy), in 
PDT the drugs themselves can (and should) be corn 
pletely innocuous until "activated” with light by an 
attending physician. Thus a level of control and selec 
tivity may be attained which is not otherwise possible. 
At present, diamagnetic porphyrins and their deriva 
tives are considered the dyes of choice for PDT. It has 
been known for decades that porphyrins, such as hema 
toporphyrin, localize selectively in rapidly growing 
tissues including sarcomas and carcinomas, although 
the reasons for this selectivity remain recondite. Cur 
rently most attention is focusing on the so-called hema 
toporphyrin derivative (HPD),25721 an incompletely 
characterized mixture of monomeric and oligomeric 
porphyrins produced by treating hematoporphyrin di 
hydrochloride with acetic acid-sulfuric acid followed 
by dilute base.2227 Fractions rich in the oligomeric 
species, which are believed to have the best tumor 
5,292,414 
47 
localizing ability,23.26 are marketed under the trade 
name Photofirin II (R) (PII) and are currently undergo 
ing phase III clinical trials for obstructed endobronchial 
tumors and superficial bladder tumors. Here, the mech 
anism of action is thought to be largely, if not entirely, 
due to the photoproduction of singlet oxygen (O2(1)), 
although alternative mechanisms of action, including 
those involving superoxide anion or hydroxyl and/or 
porphyrin-based radicals cannot be entirely ruled 
out.28-33 
Singlet oxygen is also believed to be the critical toxic 
species operative in experimental photsensitized blood 
purification procedures.339 This very new application 
of photodynamic therapy is of tremendous potential 
importance: It may provide a safe and effective means 
of removing enveloped viruses such as HIV-1, herpes 
simplex (HSV), cytomegalovirus (CMV), various forms 
of hepatitis, as well as other opportunistic blood-borne 
infections (e.g. bacteria and malaria plasmodium) from 
transfused whole blood. Given that AIDS is currently 
an ineffectively treated and usually fatal disease, the 
benefit of such a blood purification procedure would be 
of inestimable value. 
At present, sexual relations and needle-sharing are the 
dominant mechanisms for the spread of AIDS. An 
increasing percentage of AIDS infections, however, are 
now occurring as a result of blood transfusions. 103 
Unfortunately, banked blood components are essential 
products for the practice of modern medicine and as a 
result this method of transmission is not likely to be 
precluded by simple changes in lifestyle. Rather, an 
absolutely fail-proof means must be developed to insure 
that all stored blood samples are free of the AIDS virus 
(and ideally all other blood-borne pathogens). To a 
certain extent this can be accomplished by screening the 
donors' histories and carrying out serologic tests. At 
present, however, the serologic tests for HIV-1 are 
insufficient to detect all infected blood samples, in par 
ticular, those derived from donors who have contacted 
the disease but not yet produced detectable an 
tibodies.2. In addition, new mutants of the AIDS 
virus have been detected; some or all of these may es 
cape detection by current means. Thus, an antiviral 
system is needed which removes any form of HIV-1 
from stored blood. This is particularly important since a 
stored blood sample from one infected donor could 
potentially end up being administered to several differ 
ent patients, in, for instance, the course of pediatric 
Cae. 
Ideally, any blood purification procedure used to 
remove AIDS virus or other blood-borne pathogens 
should operate without introducing undesirable toxins, 
damaging normal blood components, or inducing the 
formation of harmful metabolites. In general, this pre 
cludes the use of common antiviral systems such as 
those based on heating, UV irradiation, or purely chem 
ical means. A promising approach is the photodynamic 
one alluded to above. Here, preliminary studies, carried 
out by collaborators at the Baylor Research Founda 
tion, Dr. Matthews and his team,337 and others,88-39 
have served to show that HPD and PII, in far lower 
dosages than are required for tumor treatment, can act 
as efficient photosensitizers for the photo-deactivation 
of cell-free HIV-1, HIV, hepatitis and other enveloped 
viruses. On the basis of available data, it is considered 
likely that the success of this procedure derives from 
the fact that these dyes localize selectively at or near the 
morphologically characteristic, and physiologically 












formation of singlet oxygen upon photoirradiation. The 
singlet oxygen so produced is believed, in turn, to de 
stroy the essential membrane envelope. This kills the 
virus and eliminates infectivity. Photodynamic blood 
purification procedures, therefore, apparently rely on 
the use of photosensitizers which localize selectively at 
viral membranes, just as more classic tumor treatments 
require dyes that are absorbed or retained preferentially 
at tumor sites. To the extent that this is true, simple 
enveloped DNA viruses like HSV-1 will prove to be 
good models for testing putative photosensitizers for 
potential use in killing the far more hazardous HIV-1 
retrovirus. It is important to note, however, that this 
correspondence holds only as far as freely circulating 
(as opposed to intracellular) viruses are concerned. 
Complete prophylactic removal of HIV-1 from blood 
products will require the destructive removal of the 
virus from within monocytes and T lymphocytes.' 
Critical as are the potential anti-tumor and anti-viral 
photodynamic applications which are currently being 
explored using HPD and PII, it is important to realize 
that these photosensitizers are not ideal. Indeed, this 
"first generation' of dyes suffers from a number of 
serious deficiencies which may in fact militate against 
their eventual use in biomedical applications. They 
contain a range of chemical species, they are neither 
catabolized nor excreted rapidly from the body, and 
they absorb but poorly in the red part of the spectrum 
where blood and other bodily tissues are most tran 
sparent. Each of these deficiencies can and does have 
important clinical consequences. For instance, the fact 
that HPD and PII do not contain a single chemically 
well-defined constituent, coupled with the fact that the 
active components have yet to be identified with cer 
tainty,23-27 means that the effective concentrations can 
and often do vary from preparation to preparation. 
Thus the dosage, and the light fluence, cannot necessar 
ily be optimized and predetermined for any particular 
application. Moreover, the fact that they are not metab 
olized rapidly means that significant quantities of these 
dyes will remain in stored blood units after prophylactic 
photoinduced HIV-1 removal and remain in patients' 
bodies long after photodynamic tumor treatment. The 
latter retention problem, in particular, is known to be 
quite serious: HPD and PII localize in the skin and 
induce photosensitivity in patients for weeks after ad 
ministration.5,45 
It is, however, the last of the above shortcomings (the 
lack of a truly low-energy transition) that is considered 
to be most serious: Because the longest wavelength 
absorption maximum for these dyes falls at 630 nm, 
most of the incipient energy used in photo-treatment is 
dispersed or attenuated before reaching the center of a 
deep-seated tumor and as a result little of the initial light 
is available for singlet oxygen production and thera 
py. Indeed, one study, which used a mouse model 
and a 3 mm tumor implanted beneath the skin served to 
indicate that as much as 90% of the energy is lost by the 
base of the tumor.6As illustrated by the data in FIG. 
22, taken from ref. 47, far more effective treatment 
deep-seated or large tumors might be possible if photo 
sensitizers could be developed which absorb in the 
>700 nm region, provided, of course, they retain the 
desirable features of HPD and PII (e.g. selective local 
ization in target tissues and low dark toxicity). The 
present aspect of the invention involves development of 
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such improved photosensitizers for use in photdynamic 
tumor treatment and blood purification protocols. 
1. Easily available 
2. Low intrinsic toxicity 
3. Long wavelength absorption 
4. Efficient photosensitizer for singlet oxygen produc 
tion 
5. Fair solubility in water 
6. Selective up-take in tumor tissue and/or 
7. Showing high affinity for enveloped viruses 
8. Quick degradation and/or elimination after use 
9. Chemically pure and stable 
10. Easily subject to synthetic modification 
The list summarizes those features which would be 
desirable in biomedical photosensitizers. Clearly, there 
is going to be some variability in the requirements, 
depending on application. For instance, photosensitiz 
ers designed for use in blood purification protocols 
should be designed to be less chemically stable than 
those used for photodynamic therapy. The idea being, 
that following irradiation the dyes will undergo rapid 
degradation or hydrolysis to yield nontoxic and nonac 
tive metabolites. For tumor treatment, greater stability 
appears desirable as longer times are apparently re 
quired to achieve selective localization in the neoplastic 
tissues. In both cases, of course, low toxicity and good 
long-wavelength absorption and photosensitization 
properties are an absolute must. 
In recent years, considerable effort has been devoted 
to the synthesis and study of new potential photosensi 
tizers which might meet these desiderata. Although a 
few of these have consisted of classic dyes such as those 
of the rhodamine and cyanine classes,951 many have 
been porphyrin derivatives with extended at net 
works.6-67 Included in this latter category (See FIG. 
23) are the purpurins (e.g. 1D) and verdins'6 (e.g. 2B) 
of Morgan and other chlorophyll-like species,759 of the 
benz-fused prophyrins (3D) of Dolphin et al.,60 and the 
sulfonated phthalocyanines and napthophthalocyanines 
(4D) studied by Ben-Hur,61 Rodgers,62 and others.63-67 
Of these, only the napthophthalocyanines absorb effi 
ciently in the most desirable >700 nm spectral region. 
Unfortunately, these particular dyes are difficult to 
prepare in a chemically pure, water soluble form and 
are relatively inefficient photosensitizers for singlet 
oxygen production, perhaps even acting photodynami 
cally via other oxygen derived toxins (e.g. superoxide). 
Thus a search continues for yet a "third generation' of 
photosensitizers which might better meet the ten criti 
cal criteria listed above. 
It is an important aspect of the present invention that 
an improved "third generation' of photosensitizers can 
be obtained using large, pyrrole-containing "expanded 
porphyrins'. These systems, being completely syn 
thetic, can, at least in principle, be tuned so as to incor 
porate any desired properties. Unfortunately, the chem 
istry of such systems is still in its infancy: In marked 
contrast to the literature of the porphyrins, and related 
tetrapyrrolic systems (e.g. phthalocyanines, chlorins, 
etc.), there are only a few reports of larger pyrrole-con 
taining systems, and only a few of these meet the crite 
rion of aromaticity deemed essential for long 
wavelength absorption and singlet oxygen photosensiti 
zation.68 Indeed, to date, in addition to the present in 
ventors studies of texaphrin 5D,69 (see FIG. 23), and 
"sapphyrin' 6D, first produced by the groups of Wood 
ward 70 and Johnson, there appear to be only two large 











tosensitizers. These are the "platyrins' of LeGoff (ex 
emplified by 22platyrin 7D)72 and the vinylogous por 
phyrins of Franck (represented by 26porphyrin 8D).73 
Unfortunately, to date, little has been published on the 
photodynamic aspects of these materials, although com 
ments have been included in the most recent synthetic 
reports which suggest that such studies are in progress. 
The present studies, however, of expanded porphyrins 
5D and 6D, indicate that an expanded porphyrin ap 
proach to photodynamic therapy is potentially quite 
promising. Interestingly, the porphycenes (e.g. 9D), a 
novel class of "contracted porphyrins' also show sub 
stantial promise as potential photosensitizers.75 
The present invention involves a major breakthrough 
in the area of ligand design and synthesis: synthesis the 
first rationally designed aromatic pentadentate macro 
cyclic ligand, the tripyrroledimethine-derived "ex 
panded porphyrin'5D.69 This compound, to which the 
trivial name "texaphyrin' has been assigned, is capable 
of existing in both its free-base form and of supporting 
the formation of hydrolytically stable 1:1 complexes 
with a variety of metal cations, including a number, 
such as CdZ-t, Hg2+, In3+, Y3+, Ndl3+, Eu3+, Sm3+, 
and Gd3+, that is too large to be accommodated in a 
stable fashion within the 20% smaller tetradentate bind 
ing core of the well-studied porphyrins. In addition, 
since the free-base form of 5D is a monoanionic ligand, 
the texaphyrin complexes formed from divalent and 
trivalent metal cations remain positively charged at 
neutral pH. As a result, many of these complexes are 
quite water soluble-at least far more so than the analo 
gous porphyrin complexes. 
To date, two X-ray crystal structures of two different 
Cd2+ adducts have been obtained, one of the coordina 
tively saturated, pentagonal bipyramidal bispyridine 
complex;69 the other of a coordinatively unsaturated 
pentagonal pyramidal benzimidazole complex.69. Im 
portantly, both confirm the planar pentadentate struc 
ture of this new ligand system and support the assign 
ment of this prototypical "expanded porphyrin' as aro 
natic. 
Further support for the aromatic formulation comes 
from the optical properties of 5D. For instance, the 
lowest energy Q-type band of the structurally charac 
terized bispyridine cadmium(II) complex of 5D at 767 
nn (k=51,900) in CHCl3 is both considerably more 
intense (by roughly a factor of 10) and substantially red 
shifted (by almost 200 nm) as compared to that of a 
typical reference cadmium(II) prophyrin. Of further 
interest is the fact that compound 5D and both its zinc 
(II) and cadmium(II) complexes are very effective pho 
tosensitizers for singlet oxygen, giving quantum yields 
for 102 formation of between 60 and 70% when irradi 
ated at 354 nm in air-saturated methanol.99. It is these 
latter remarkable properties which make these systems 
potentially ideal candidates for use in photodynamic 
therapy and blood purification protocols. 
A variety of new aromatic tripyrroledimethine 
derived macrocyclic ligands analogous to compound 
5D above now been prepared and more are planned. A 
number of these, e.g. 10D-15D (see FIG. 25) have al 
ready been synthesized and found to form metal com 
plexes as texaphrin 5D and many others can easily be 
conceived. This aspect of the present invention involves 
preparation of new analogues of the original texaphrin 
and elucidation of their chemical and photobiological 
properties. Of importance is the fact that, by making 
ostensibly minor substitutions, one may "tune' at will 
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the energy of the lowest Q-type band. For instance in 
the sequence of cadmium(II) complexes derived from 
14D, 5D and 16D (which have already been examined), 
this transition ranges from 690 to 880 nml Thus, it ap 
pears at present, as if the optical properties of the texa 
phyrin-type expanded porphyrins can be matched to 
any desired laser frequency. Again, this is a feature that 
suggests that this class of dyes will be well-suited for a 
variety of photodynamic applications. 
Several preliminary in vitro biological studies have 
been carried out with the cadmium(II) complexes of the 
18 and 22 T-electron texaphyrins 14D and 5D. These 
results, although limited in scope, are encouraging. For 
instance, both complexes effect a ca. 2 log photokilling 
10 
of HSV-1 infectivity upon irradiation with 20 J/cm2 of 15 
light at the lowest energy absorption (690 nm and 767 
nm, respectively), yet, importantly, neither 5D nor 14D 
show any appreciable dark antiviral activity (nor, fortu 
nately, do they show much evidence of general cytotox 
icity in the absence of light). In addition, the 22 at-elec 
tron cadmium-containing texaphyrin 5D has been shown 
by both absorption and emission measurements to local 
ize selectively on lymphocytes. This latter result, in 
particular, augurs well for the eventual use of these 
materials in prophylactic photodynamic anti-AIDS 
blood-treatment programs. The 2 log decrease in 
HSV-1 activity achieved with the texaphyrin systems 
studied to date is not yet sufficient to completely design 
a viable protocol: Both HPD and PII, as well as sapphy 
rin (6D), reprepared by literature methods provide 
about a 5 log decrease in viral activity under similar 
light fluence when irradiated at the appropriate lowest 
energy transition (630 and 690 nm, respectively). Al 
though a mechanistic comparison with the incompletely 
chracterized hematoporphyrin-derived systems is diffi 
cult, a direct structural correspondence exists between 
the tripyrroledimethine-derived cadmium(II) texaphy 
rin and free-base sapphyrin systems: The main differ 
ence is in overall charge on the photosensitizer. It may 
thus be that these two macrocycle types are bound to 
the virus envelope in a different manner; perhaps the 
sapphyrin "intercalates' into the lipid layer and the 
charged metallotexaphyrin sits on the surface of the 
membrane and as such could suffer from deleterious 
aggregations (which would lower singlet oxygen pro 
duction). The critical observational difference between 
these two closely related systems (texaphyrin vs. sap 
phyrin) suggests that small structural differences may 
be reflected in significant functional effects. In addition, 
these experimental findings suggest that: 1) The free 
base texaphyrin system should be a far more efficient 
photosensitizer for in vitro and in vivo applications that 
the cadmium complexes studied so far, and that 2) ad 
justing the substituents on the texaphyrin periphery 
should serve to alter the key biodistribution properties 
of the metalated and metal-free systems. Even if all 
attempts to augment the photodynamic antiviral effi 
ciency of texaphyrin meet with failure (a result we 
consider highly unlikely), it is probable that this new 
photosensitizer will find applications in more classic 
tumor-treating procedures: the 18 ar-electron cadmium 
containing macrocyclic system 14D, for instance, has 
already been shown to effect a roughly 4 log photokill 
of Daudi-strain leukemic cells. 
The synthesis of texaphyrin 5Dis summarized in FIG. 
26. It involved three major steps. The first is the synthe 
sis of the tripyrrane 19D. This crucial intermediate is 










alyzed condensation between pyrroles 17D and 18D, 
Following deprotection and formylation the key difor 
myl tripyrrane precursor 21D is obtained in yields ex 
ceeding 80% based on 17D. Condensation of this tripyr 
rane with O-phenylenediamine constitutes the second 
critical step in the synthetic pathway. Fortunately, this 
reaction proceeds in virtually quantitative yield and 
gives the sp3 hybridized form of the "texaphyrin" skele 
ton, 22D, directly.76 The final critical step then involves 
oxidation and, as appropriate, concurrent metal binding. 
In the case of Cd2+, Hg2+, and Zn2+, the aromatic, sp? 
hybridized, form of the macrocycle (5D) is obtained in 
roughly 25% yield by simply stirring the starting sp 
hybridized precursor (22D) with the appropriate salt in 
the presence of oxygen.69Such a simple metal insertion 
and oxidation procedure, however, fails for cations of 
the lanthanide series. Here, a combination of metal salt, 
proton sponge (R) (N,N',N',N'-tetramethyl-1,8- 
diaminonaphthalene), and oxygen are required to effect 
oxidation and metal insertion. Interestingly, the use of a 
proton sponge alone gave the free-base form of the 
ligand directly, but unfortunately in only ca. 10% yield. 
Efforts to optimize this latter yield are still in progress. 
By using a variety of other substituted diamines and 
/or diformyl tripyrranes, it has already proved possible 
to generate a range of other tripyrroledimethine 
derived macrocycles including compounds 10D-16D 
(FIG. 25), 1 E-7E, 8E,9E (FIG. 31), 23D, 2.5D, 26D (FIG. 
27) those skilled in the art will be able to prepare many 
more. For instance, by using the appropriate diamine 
and/or diformyl tripyrrane, those skilled in the art will 
be able to generate the modified texaphyrins 24D, 
27D-30D shown in FIG. 27, where in the cases of the 
generalized structures of 29D and 30D, the substituents 
R1, R2, R3, R4, and R5 may be separately and indepen 
dently H, alkyl, amino, hydroxy, alkyoxy, carboxy, 
carboxamide, ester, amide, sulfonato, or substituted 
alkyl, substituted alkoxy, substituted ester, or substi 
tuted amide and the metal, M, may be any di- or triva 
lent metal cation with the charge, n, adjusted as appro 
priate as an integral value between -5 and +5. Here, as 
would be apparent to one skilled in the art, the charge 
n nould be adjusted so as to account for the choice of 
metal, M the pH under consideration, and the substitu 
ents R1-R5. For instance, if R = carboxyl and R2-R5. 
= alkyl and the metal, M= Gd+3, and the solution 
pH=7 (so that R1 = CO2), the charge n would be 
Zeo 
A further advantage of developing a wide variety of 
solubilized texaphyrins is that many of these would be 
suitable for further functionalization. For instance, 
treatment of texaphyrins 7E, 25D, 26D, 27D, 28D, or 29D 
with thionyl chloride or p-nitrophenol acetate would 
generate activated acyl species suitable for attachment 
to monoclonal antibodies or other biomolecules of in 
terest. Alternatively, standard in situ coupling methods 
(e.g. DCCI) could be used to effect the same sort of 
conjugation. In either case, the ability to attach and 
deliver a potent photosensitizer or active radioisotope . 
directly to a tumor locus could have tremendous poten 
tial benefit in the treatment and/or detection of neoplas 
tic disorders." 
All of the texaphyrin systems prepared to date, and 
all the new target systems proposed above, involve an 
imine-containing macrocyclic core. The use of such a 
linking group offers both advantages and disadvantages. 
The primary advantage is that macrocyclic systems 
containing such subunits are easy to prepare and gener 
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ally act as effective ligands (this is certainly true for 
texaphyrin). On the other hand, they are thermody 
namically unstable with regards to hydrolysis, al 
though, at least in the case of texaphyrin 5D, this is less 
of a problem than one might expect. For instance, the 
half-lives for imine hydrolysis of the best-studied cadmi 
um-containing complex of 5D and gadolinium com 
plexes, 2B and 7B (FIG. 17) are both in excess of 30 days 
at pH 7 and several hours at pH 2. Nonetheless, applica 
tions could be envisioned where greater stability might 
be required. For this reason the synthesis of the two 
methine-linked texaphyrin analogues 31D and 32D in 
which the weakest CH=N link has been replaced by a 
more robust CH-CH subunit (See FIG.28) is an aim of 
this invention. It is an expectation that compounds 31D 
and 32D may be prepared using either standard Wittig 
based ring closures, which have proved useful in the 
synthesis of large, furan-containing annulenes,78 or via 
McMurry-type couplings, such as those that have re 
cently proved useful in the synthesis of porphycenes.74 
Once in hand, all new texaphyrin systems will be 
characterized fully using normal spectroscopic and 
analytical means, including, where possible X-ray dif 
fraction methods. In addition, a complete analysis of the 
optical properties will be made for all new systems 
under a range of experimental conditions including 
some designed to approximate those which might per 
tain in vivo. Initial measurements such as simple record 
ing of the optical absorption and emission spectra will 
be carried out in the P.I.'s laboratory. More detailed 
analyses, including triplet lifetime and singlet oxygen 
quantum yield determinations, will be carried out. The 
objective of this part of the proposed research program 
is to obtain a complete ground and excited state reactiv 
ity profile for each and every new texaphyrin produced. 
Questions such as when is singlet oxygen production 
maximized, how is the quantum yield for its formation 
influenced by the position of the lowest energy (Q-type) 
transition, whether aggregation is more prevalent in 
certain solvents or in the presence of certain biologi 
cally important components (e.g. lipids, proteins, etc.), 
and, finally, whether significant differences in in vitro 
optical properties are derived from the use of elaborated 
texaphyrins bearing cationic, anionic, or neutral substit 
uents all will be thus answered. 
Once the above complexes are made, screening ex 
periments are carried out. Standard in vitro protocols 
will be used to evaluate the in vitro photokilling ability 
of the texaphyrin derivatives in question. For instance, 
the dyes of choice will be administered in varying con 
centrations to a variety of cancerous cells and the rate 
of replication determined both in the presence and ab 
sence of light. Similarly, dyes of choice will be added to 
standard viral cultures and the rate of growth retarda 
tion determined in the presence and absence of light. 
Where appropriate, a variety of solubilizing carriers 
will be used to augment the solubility and/or mono 
meric nature of the texaphyrin photosensitizers and the 
effect, if any, that these carriers have in adjusting the 
biodistribution properties of the dyes will be assessed 
(using primarily fluorescence spectroscopy). It should 
be stressed, of course, that in all cases appropriate con 
trol experiments will be carried out with normal cells so 
that the intrinsic dark and light toxicity of the texaphy 
rins may be determined. 
From a generalized set of in vitro experimental proce 
dures, it is expected that a clear picture of the photody 
namic capabilities of the texaphyrin system will emerge. 












reactivity will be addressed and answered in what is 
(hopefully) an unambiguous fashion. In addition, some 
preliminary toxicity and stability information will begin 
to emerge from these in vitro experiments. Here ques 
tions of interest include how long the texaphyrin system 
is holding up under physiological conditions and 
whether the nature of the central metal influences this 
stability. Equally, or perhaps more important is the 
question of whether the central cation is affecting cyto 
toxicity. As discussed in papers published by the present 
inventors,8969d it is not possible to remove the larger 
bound cations (e.g. Cd2+ or Gd3+) by simple chemical 
means (Zn2+, however, appears to "fall out” with ease). 
Moreover, preliminary results suggest that the best 
studied cadmium(II)-containing texaphyrin complex 5D 
is not appreciable cytotoxic. Nonetheless, the question 
of intrinsic toxicity is one of such central importance 
that the cytotoxicity of all new systems will be screened 
in vitro and, where deemed appropriate, further in vivo 
toxicity studies will also be carried out. 
Once in vitro screening experiments are complete, 
samples of potential photosensitizers that look particu 
larly promising will be selected for further develop 
ment. Those that possess the best combination of stabil 
ity and photodynamic ability for use in blood treatment 
protocols will be further evaluated in flow system using 
whole blood samples. Those that look promising for 
tumor treatment will be subjected to further animal 
screening. 
This aspect of the present invention involves the 
coordination and photochemical properties of tripyr 
roledimethine-derived "texaphyrins', a new class of 
"expanded prophyrins', the first members of which 
have been recently prepared and characterized in our 
laboratory. It is expected that these basic studies will 
lead to the development of viable procedures of remov 
ing HIV-1 and other enveloped viruses from transfused 
blood as well as improved means of detecting and treat 
ing tumors. The long range goals exemplified here are 
to: 
1. Synthesize further safe and efficient photosensitizers 
for use in killing human immunodeficiency virus 
(HIV-1) and other enveloped viruses in blood, which 
operate without harm to normal blood components. 
2. Develop new safe and effective photosensitizers for 
use in the in vivo photodynamic treatment of tumors. 
The approach to these long range objectives centers 
around the preparation and use of suitably modified 
tripyrrole-dimethine derived texaphyrin-type expanded 
porphyrins. This is an essential first step towards the 
realization of the above goals. Specific extensions of the 
present invention include: 
1. Explore further the coordination and general chemi 
cal properties of our original texaphyrin and existing 
analogues and obtain a complete solubility, stability, 
and reactivity profile for those complexes deemed 
likely to be of greatest biomedical interest. 
2. Synthesize simple analogues of the currently avail 
able texaphyrins with cationic, anionic, or neutral 
substituents and study how such modifications alter 
the water solubility and biodistribution properties of 
these expanded porphyrins. 
3. Make analogues of texaphyrin which contain reactive 
nucleophilic or electrophilic substituents suitable for 
conjugation to monoclonal antibodies or other bi 
omolecules of potential interest. 
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4. Prepare new texaphyrin-type aromatic macrocycles 
in which the key imine (CH-N) functionality has 
been replaced with a presumably more robust meth 
ine (CH=CH) linkage. 
5. Carry out complete photochemical studies of all new 
texaphyrins so as to determine unambiguously those 
factors (e.g. 'na) which maximize singlet oxygen 
production, 
6. Test the in vitro photodynamic tumor and virus kill 
ing efficiency of the new texaphyrins prepared in the 
course of the synthetic phase of this project. 
7. Test the in vivo photodynamic anti-tumor properties 
of the more promising texaphyrins synthesized and 
screened as outlined above. 
Literature citations in the following list are incorpo 
rated by reference herein for the reasons cited. 
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EXAMPLE 6 
One aspect of the utility of the present invention is 
exemplified by use of complexes described herein for 
photon-induced deactivation of viruses and virally in 
fected or potentially infected encaryotic cells. The gen 
eral photodeactivation method used in this example was 
developed by the Infectious Disease and Advanced 
Laser Applications Laboratories of the Baylor Re 
search Foundation, Dallas, Tex. and is a subject of a 
U.S. patent application filed Jun. 25, 1987 by Millard 
Monroe Judy, James Lester Matthews, Joseph Thomas 
Newman and Franklin Sogandares-Bernal (assigned to 
the Baylor Research Foundation, Dallas, Tex.). 
The efficiency of some of the porphyrin-like macro 
cycles in photosensitized inactivation of Herpes Sim 
plex Virus Type 1 (HSV-1) and of human lymphocytes 
and monocytes, both peripheral mononucleated vascu 
lar cells (PMC) and cellular hosts of HIV-1 has been 
initiated. Previous studies of viral inactivation using the 
macrocyclic photosensitizers dihematoporphyrin ether 
(DHE) or hematoporphyrin derivative (HPD) have 
shown that with the porphyrins, only those viruses 
studied which are enveloped or possess a membraneous 
coat are inactivated. The enveloped viruses studied 
include HSV-1, cytomegalovirus, measles virus, and 
the human immunodeficiency virus HIV-12. 
The photosensitized inactivation of Herpes Simplex 
Virus, Type 1 (HSV-1) was investigated in culture me 
dium using various macrocycles of the present inven 
tion. Results are listed in Table 4. 
TABLE 4 
Herpes Simplex Virus I. Inactivation with Assymmetric 
- Expanded Porphyrin Macrocycle Complexes-- 
% Survival Viral 
Complex" Conc. (M) Infectivity 













Herpes Simplex Virus I Inactivation with Assymmetric 
Expanded Porphyrin Macrocycle Complexes 
% Survival Vira 
Conc. (M) Infectivity 
0.40 00 
All light irradiation at max absorption and to give a light fluence of 10 J/cm 
Structural formulas in FGS. 4 and 25. 
Complex 
The three cadmium-containing macrocycles (34, 10D 
(where M is Cd), and 14D (where M is Cd) at concen 
trations of 20 M demonstrated 290% viral inactiva 
tion as judged by viral plaque assay. 
The macrocycle photosensitizing studies employed 
enveloped HSV-1 as the model for screening based on 
its ease of propagation and assessment of infectivity in 
cell culture. The screening procedure for photoinacti 
vation of HSV-1 was similar to the methods previously 
described. Essentially, selected macrocycles at differ 
ent concentrations were added to a cell-free suspension 
of 106 PFU/ml of HSV-1. The viral suspensions were 
irradiated at the optimal absorption wavelength of the 
selected dye at different light-energy densities. Controls 
consisted of (1) nonirradiated virus, (2) virus irradiated 
in the absence of macrocycle, and (3) virus treated with 
selected concentrations of macrocycle and maintained 
in the dark. All samples were then assessed for viral 
infectivity by determining the number of PFU/ml in 
Vero cells. 
Viral suspensions were serially diluted and subse 
quently absorbed onto Vero cell monolayers for 1. 
hours at 37 C. An overlay medium was added and the 
cells incubated at 37-C for 3-4 days. The overlay me 
dium was then removed, the monolayers fixed with 
methanol and tinctured with Giemsa, and individual 
plaques counted under a dissecting microscope, Unin 
fected cell cultures also were exposed to the macrocy 
cle complexes to rule out direct cytotoxic effects. 
The inactivation of PMC's in the absence and pres 
ence of light after exposure to concentrations of com 
plex 34 in whole human plasma ranging from 0.015 to 38 
uM is shown in FIGS. 29 and 30. Inactivation was 
judged by mitogenic assay. Toxicity onset with 3A (see 
FIG. 4) and 1c (see FIG. 17) in the absence of light was 
between 0.15 and 1.5 L.M (FIG. 29). As shown by mito 
genic assay in FIG. 30, aerobic photosensitization of 
cells exposed to 34 at 0.15 M concentration and 20 
joules/cm2 of 770 nm wavelength light caused signifi 
cant inhibition of the cellular division of PMC's. Mod 
erate increase in either photosensitizer concentration or 
light dosage is expected to result in essentially complete 
cellular inactivation. 
The results to date, some of which are summarized 
herein, indicate strongly that the expanded porphyrin 
like macrocycles of the present invention should be 
efficient photosensitizers for free HIV-1 and infected 
mononuclear cells as well. Altering the polarity and 
electrical charges of side groups of these macrocycles is 
anticipated to alter markedly the degree, rate, and per 
haps site(s) of binding to free enveloped viruses such as 
HIV-1 and to virally-infected peripheral mononuclear 
cells. These substituent changes are also expected to 
modulate photosensitizer take-up and photosensitiza 
tion of leukemia or lymphoma cells contaminating 
bone-marrow as well as by normal cells of the marrow. 
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EXAMPLE 7 
This example summarizes certain of the basic five 
coordinate (pentadentate), expanded porphyrin com 
pounds and complexes of the present invention and 
their derivatives which have been synthesized. In FIG. 
31, compounds 1 E-7E, 14D and 15D are shown. Varia 
tions include changes in the ortho-phenylene-diamino 
substituent, namely R1 and R2 and in the nature of the 
starting diamine itself. When both Ri and R2 on the 
ortho phenylene diamino substitutent are hydrogen as 
in compound 1E the basic structure of texaphyrin is 
shown. These R1 and R2 substituents may also both be 
methyl, CH3 (compound 2E). Additionally when R is 
H, R2 may be chloride (compound 3E); bromine (com 
pound 4E); nitro (compound 5E); methoxy (compound 
6E); or carboxy (compound 7E) When M is hydrogen, 
the complex has a charge of 0 (n=0). When M is a 
divalent metal such as mercury 2, cadmium-2, zinc, 
cobalt+2 or manganese+2; the charge of the complex 
will be + 1 (n=1). When M is a trivalent metal cation 
such as europium-3, neodynium-3, samarium, lan 
thanum+3, gadolinium+3, indium+3 or yttrium+3 the 
charge of the complex will be +2 (n=2). For the com 
plexes marked with a single asterisk (1E and 2E) all 
metals, divalent or trivalent mentioned above have been 
included in various formed complexes. Complexes with 
a double asterisk (3E-6E) have been synthesized as ei 
ther the zinc or cadmium derivative (M=Zn or Cd; 
n = 1). While many other usable compounds are men 
tioned in other sections of this application, or could be 
readily synthesized by those of skill in the art from the 
directions included herein, the particular ones men 
tioned in this Example are thought to be especially 
useful for many purposes, for example, those involving 
purifying biological samples of viruses, particularly 
retroviruses. These compounds should also be useful for 
processes such as, for example, photodynamic cancer 
therapy, magnetic resonance imaging (MRI) enhance 
ment and antibody functionalization as mentioned else 
where herein. 
EXAMPLE 8 
Magnetic Resonance Imaging Enhancement 
In many respects the key to cancer control lies as 
much, if not more, in early detection and diagnosis as it 
does in subsequent therapeutic management. New tech 
niques which allow neoplastic tissue to be observed and 
recognized at an early stage of development thus have a 
critical role to play in the battle against these disorders. 
One such promising technique is magnetic resonance 
imaging (MRI). Although quite new, this noninva 
sive, apparently innocuous method, is not firmly en 
trenched as a diagnostic tool of prime importance, com 
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plementing or, in some cases, supplanting computer 
assisted X-ray tomography as the method of choice for 
solid tumor detection. 
The physical basis of current MRI methods has its 
origin in the fact that in a strong magnetic field the 
nuclear spins of water protons in different tissues relax 
back to equilibrium at different rates, when subject to 
perturbation from the resting Boltzman distribution by 
the application of a short rf pulse.2. For the most com 
mon type of spin-echo imaging, return to equilibrium 
takes place in accord with equation 1 and is governed 
by two time constants T1 and T2, the longitudinal and 
transverse relaxation times, respectively. 
SI=(HH()(esp(-TE/T2)}{1-exp(-TR/T)} (1) 
Here, SI represents the signal intensity, H is the con 
centration of water protons in some arbitrary volume 
element (termed a voxel), H() a motion factor corre 
sponding to motion (if any) in and out of this volume 
element, and TE and TR are the echo-delay time and the 
pulse-repetition times, respectively. The various pulse 
sequences associated with obtaining an MRI image thus 
correspond to choosing TE and TR by setting the times 
associated with (and between) the excitation and inter 
rogation rf pulses (the first to perturb the system, the 
second to determine the extent of return to equilibrium) 
and determining SI, which, as illustrated above, is func 
tion of the particular T and T2 values in force. Since 
both T and T2 are a function of the local (bulk) mag 
netic environment, and as such are a function of the 
particular tissue in which the water proton is situated, 
differences in these values (and hence SI) allow for 
image reconstruction. Of course, only when these local, 
tissue-dependent, relaxation differences are large can 
tissue differentiation be effected. 
In practice for biological systems, T2 values are very 
short (and TE and TR are chosen to accentuate this 
situation). Thus it is differences in the longitudinal time 
constant (T) which dominate relaxation effects and 
relative signal intensity: Decreases in T1 correspond to 
increasing signal intensity. Any factors, therefore, 
which will serve to decrease T1 selectively for a partic 
ular tissue or organ will thus lead to increased intensity 
for that area and better contrast (signal to noise) relative 
to the bulk animal background. This is where paramag 
netic MRI contrast agents come into play. 
It has been known since the earliest days of magnetic 
resonance spectroscopy that paramagnetic compounds, 
containing one or more unpaired spins, enhance the 
relaxation rates for the water protons in which they are 
dissolved. The extent of this enhancement, termed 
relaxivity, is, in the absence of colligative interactions, 
given by Ri (in units of M-1s-1 or mM-1s-1) in eq. 
24,5 
(l/T)obsd=(1/T)d--RM is 1,2 (2) 
Here, (1/Ti)obsd is the reciprocal of the observed relax 
ation time in the presence of a paramagnetic species M, 
and (1/T) is the observed relaxations time in its ab 
sence. The relaxivity of any given paramagnetic species, 
i.e., metal complexes for MRI enhancement, is depen 
dent on the magnitude of the dipole-dipole interactions 
between the electron spin (on the metal) and the proton 
spin (on the water). The extent of this interaction is 
strongly dependent on the nature of the interaction 
between the paramagnetic complex and the water mole 











to define both "inner sphere' and "outer sphere" contri 
butions to the total relaxivity R4.5 The former account 
for water molecules which participate directly in the 
coordination sphere of the metal; the latter for all other 
loose interactions (e.g. hydrogen bonding and transla 
tional diffusion of waters bound in the second coordina 
tion sphere). Where chemically viable, it is, in general, 
inner sphere relaxation which dominates R. For this 
interaction, the contribution to the longitudinal relax 
ation is given by equation 3. 
(1/T)(inner sphere)=PMg/TM-M) (3) 
Here, PM is the mole fraction of metalion, q is the num 
ber of bound water molecules, t is the lifetime of the 
bound water, and TM is the relaxation time of the 
bound water protons. The value of this latter term is 
approximated by the Solomon-Bloembergen equations 
(eqs, 4-6) which account for both dipole-dipole 
("through space') and contact ("through-bond') 
terms." 
7t (4) 2. Yg'S(S+ 1)/32 
(1 = wit?) 6 -- 
e 
(1 = wit’) 
Here, Y1 is the proton gyromagnetic ratio, g the elec 
tronic g-factor, S the total electron spin of the paramag 
netic ion, g the Bohr magneton, r the water proton 
metalion distance, A27T/h) the electron-nuclear hyper 
fine coupling constant, and ws and withe electronic and 
proton Larmor precession frequencies, respectively. 
The dipolar and scaler correlation times to and te are 
given by: 
l/tc2 l/Tie-1/tM-1/R (5) 
l/te= 1/Tie--l/tf (6) 
where, Tle is the longitudinal electron spin relaxation 
time and tR the rotational tumbling time of the entire 
water-complex ensemble. More elaborate theoretical 
treatments are available to account for collisional relax 
ation effects and other factors which would perturb the 
static zero-field splitting of the electronic sublevels in 
inner sphere relaxation pathways. Detailed analyses are 
also available to account for contributions from outer 
sphere mechanisms. Nonetheless, for the sake of the 
present discussion, the simple Solomon-Bloembergen 
equations given above will suffice: They illustrate the 
key physical features required for a good paramagnetic 
contrast agent. 
From a physical point of view, MRI contrast agents 
require species that are highly paramagnetic (so that the 
magnetic moment term S(S+1) is large), possess large 
Tle's, and display large rotational tumbling times (tR). 
In addition, an ideal contrast agent should also bind one 
or more water molecules (so that the inner sphere relax 
ation mechanisms are operative) and exchange these 
waters at a rate (1/tM) that is optimal.,589 with the 
exception of tR, which is often set more by the effective 
viscosity of the local environment (i.e. is the complex 
"stuck' to a slowly rotating protein?0) than by the 
choice of complex, all of these factors may be influ 
enced by the choice of basic paramagnetic cation and by 
subsequent ligand design.' This ligand design, which 
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constitutes a major thrust in current MRI research, is, of 
course, also subject to very stringent biological require 
ments: Not only must the putative contrast agent be 
highly paramagnetic and achieve good relaxation en 
hancement, it must also be nontoxic at the dosages ad 
ministered, stable in vivo, excreted quickly after diagno 
sis is complete, and, of course, show desirable tissue 
localizing abilities. Taken together these criteria are 
quite severe. 
Indeed, at present, only one paramagnetic MRI con 
trast agent is in clinical use, the bis(N-methyl-gluca 
mine) salt of Gd(III) diethylenetrianinepentaacetate, 
(MEG)2Gd(DTPA)(H2O) (c.f structure 10)11-18 mar 
keted by Berlex Laboratories. This dianionic complex 
localizes selectively in extracellular regions, and is 
being used primarily in the visualization of the capillary 
lesions associated with cerebral tumors. 11-13 In 
Gd(DTPA)(H2)2, one molecule of water is bound in 
the first (inner) coordination sphere and at 37 C. in 
water this complex displays a relaxivity of 3.7 
mM-is-i at 20 MHz.919 In marked contrast to the 
simple Gd(III) complex of EDTA, for which log 
Kass=17.4 at 25 C.2021 the DTPA complex appears 
to be sufficiently thermodynamically stable (log 
Kasse-22.5 at 25 C.2021 so as to be kinetically stable 
under physiological conditions and is apparently ex 
creted intact through the kidneys within several days of 
administration. These desirable features notwithstand 
ing, it is clear that other contrast agents with superior 
kinetic stability, better relaxivity, lower net charge 
(which would lower the osmolality and hence pain 
threshold of the administered solutions), and/or differ 
ent tissue localizing capabilities would be desirable for 
clinical use. Indeed, in a recent review on the subject, 
Lauffer states that: "New synthetic methods toward 
kinetically inert complexes, especially those of Gd(III), 
need to be developed. These preferably should be versa 
tile enough to allow for specific substitutions on the 
complex that may modulate its properties.' 
To date, in fact, considerable effort has been devoted 
to the development of new potential MRI contrast 
agents.2-37 Most of this work has centered around pre 
paring new complexes of Gd(III).21-29,362,376 The em 
phasis on Gd(III) salts stems from the fact that this 
cation, with 7 unpaired f-electrons, has a higher mag 
netic moment than other paramagnetic cations such as 
Fe(III) and Mn(II).4.5 Thus, all other things being equal, 
complexes of Gd(III) would be expected to be superior 
relaxation agents than those derived from Mn(II) or 
Fe(III). In addition, both iron and, to a lesser extent, 
manganese are sequestered and stored very efficiently 
in humans (and many other organisms) by a variety of 
specialized metal-binding systems.38 Moreover both 
iron and manganese are capable of existing in a range of 
oxidation states and are known to catalyze a variety of 
deleterious Fenton-type free-radical reactions.39 
Gadolinium(III), which suffers from neither of these 
deficiencies thus appears to offer many advantages. 
Unfortunately, as is true for Fe(III) and Mn(II), the 
aqueous solution of Gd(III) is too toxic to be used di 
rectly MRI imaging at the 0.01 to 1 mM concentrations 
required for effective enhancement. Hence the em 
phasis is on developing new agents which, as is true for 
DTPA, form hydrolytically stable complexes in vivo 
with Gd(III) and/or other paramagnetic cations. A 
number of such ligands, including the very promising 
DOTA21-27 and EHPG28,29 systems, are now known 












cases, however, reliance is made on the same basic phil 
osophical approach. Specifically, for Gd(III) binding, 
carboxylates, phenolates, and/or other anionic chelat 
ing groups are being used to generate intrinsically labile 
complexes of high thermodynamic stability in the hope 
that such high thermodynamic stability will translate 
into a kinetic stability that is sufficient for in vivo appli 
cations. Indeed, little effort is currently being devoted 
to the preparation of nonlabile Gd(III) complexes that 
would in and of themselves enjoy a high kinetic stabil 
ity. The problem seems to be quite simply that such 
systems are hard to make. For instance, unlike the tran 
sition metal cations which are bound well to porphyrins 
(a synthetically versatile ligand which is readily subject 
to modification and which, at least for Mn(III)TPPS), 
and other water soluble analogues,0-3 shows good 
relaxivity and good tumor localizing properties), 
Gd(III) forms only weak and/or hydrolytically unsta 
ble complexes with porphyrins,c,340 although other 
simple macrocyclic amine- and imine-derived li 
gands36,371 will support stable complexes with certain 
members of the lanthanide series and do show some 
promise, as yet unrealized, of acting as supporting che 
lands for Gd(III)-based MRI applications. It is a prem 
ise of the present invention that nonlabile porphyrin 
like Gd(III) complexes can be generated using an "ex 
panded porphyrin' approach and that once made these 
complexes will prove to be useful contrast agents for 
MRI applications. In fact, texaphyrin is capable of stabi 
lizing complexes with a variety of di- and trivalent 
cations, including Cd2+, Hg2+, r3+, In+, and Ndl3+. 
The observation that a hydrolytically stable Nd com 
plex may be supported by texaphyrin bodes well for the 
use of texaphyrins in various gadolinium(III)-based 
MRI applications. Unfortunately, as explained in 
greater detail in Example 4, all efforts to date to isolate 
a stable Gd3+ complex from texaphyrin in good yield in 
good yield have met with failure. It is suspected that 
this is because the complex is actually so water soluble 
that standard work-up methods fail. Consistent with this 
supposition is the fact that fully characterized Sm3+, 
Eu3+, and Gd3+ (as well as Y3+) complexes have been 
prepared from the more hydrophobic dimethyl-texa 
phyrin. These complexes are obtained in roughly 25% 
yields from the corresponding reduced (methylene 
bridged) macrocyclic precursor using the standard 
metal insertion and oxidation conditions discussed 
below and in Examples 1 and 2. Importantly, all of these 
complexes are soluble in 1:1 methanol-water mixtures 
and all are quite stable under such potentially decom 
plexing conditions. The half-life of the Gd3+ complex 
in 1:1 methanol-water at room temperature, for in 
stance, is over 5 weeks. Thus it is possible to use a texa 
phyrin-type approach to generate hydrolytically stable 
gadolinium(III) complexes (something that cannot be 
achieved using simple porphyrins. Given this critical 
result, further modifications of the texaphyrin skeleton 
which should allow preparation of stable Gd3+ com 
plexes with improved water solubility or better biodis 
tribution properties. In addition, by using suitable ani 
onic side-chains, it should be possible to prepare neutral 
complexes with no net overall charge. Such complexes 
would display a lower osmolality in aqueous solution. 
This would reduce the pain associated with their admin 
istration and have positive clinical consequences. Thus 
the texaphyrin approach to MRI use of contrast agent 
development looks promising. 
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Literature citations in the following list are incorpo 
rated by reference herein for the reasons cited. 
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EXAMPLE 9 
Antibody Conjugates 
Radioisotopes have long played a central role in the 
detection and treatment of neoplastic disorders Consid 
erable research therefore continues to be devoted to 
improving their efficacity in medical applications. One 
of the more promising approaches in doing so involves 
attaching radioisotopes to tumor-directed monoclonal 
antibodies and their fragments. Such monoclonal anti 
bodies and their fragments localize selectively at tu 
mors; radiolabeled antibodies could therefore serve as 
"magic bullets" and allow the direct transport of radio 
isotopes to neoplastic sites thus minimizing whole body 
exposure to radiation. Considerable research is now 
being carried out along these lines (see references 2-11 
for general reviews). Much, but certainly not all, is 
focusing on the use of bifunctional metal chelating 
agents. It is this approach to radioimmunodiagnostics 
(RID) and therapy (RIT) that is most closely related to 
the present invention. 
Bifunctional metal chelating agents for use in anti 
body conjugate-based treatment and diagnostic applica 
tions must satisfy two critical criteria: They must be 
capable of binding the radioisotope of interest and of 
attachment to the targeted antibody. Thus, these bifunc 
tional chelating agents must 1) have functional groups 
suitable for conjugation to the antibody, 2) form cova 
lent linkages that are stable in vivo and which do not 
destroy the immunological competence of the antibody, 
3) be relatively nontoxic, and 4) bind and retain the 
radiometal of interest under physiological conditions. 
15 The last of these conditions is particularly severe. In 
contrast to MRI imaging where small concentrations of 
decomplexed cation can perhaps be tolerated, the po 
tential damage arising from "free' radioisotopes, re 
leased from the conjugate, can be very serious. Thus, 
for radioimmunological work, the condition of nonla 
bility must be strictly enforced. On the other hand, only 
nanomole concentrations of isotopes, and hence ligand, 
are generally required for RID and RIT applications, so 
that the concerns associated with intrinsic metal and/or 
free ligand toxicity are considerably relaxed. 
Needless to say, the above conditions must be met for 
each and every isotope considered for RIT and RID 
work. Thus, from the point of view of ligand design and 
synthesis, the problem becomes one of identifying an 
isotope of medical advantage, designing a suitable li 
gand and attaching it to the antibody of choice either 
before or after metal binding. Historically, there has 
been a trade-off between choosing an ideal isotope and 
one that can be readily complexed with existing difunc 
tional conjugates. 
For the purposes of imaging, an ideal isotope should 
be readily detectable by available monitoring tech 
niques and induce a minimal radiation-based toxic re 
sponse. In practice these and other necessary require 














250 KeV range, which possesses a short effective half 
life (biological and/or nuclear), decays to stable prod 
ucts, and, of course, is readily available under clinical 
conditions.24. To date, therefore, most attention has 
focused on 131I (t=193H), 123I(t= 13h),99mTc(t=6.0 
h), 67Ga(t=78h), and 111In(t=67.4h) which come 
closest to meeting these criteria.16 Each of these enjoys 
advantages and disadvantages with respect to antibody 
labeling for RID. 131I and 123, for instance, are easily 
conjugated to antibodies (and other proteins) via simple 
electrophilic aromatic substitution of tyrosine resi 
dues." As a result, these isotopes have seen wide use in 
immunological-based applications (RIT as well as 
RID). Unfortunately, such methods of conjugation are 
not particularly robust under physiological conditions 
(metabolism of 131I or 123I labeled proteins, for instance, 
produces free radioactive iodide anion) and as a result 
can lead to a fair concentration of radioactivity at sites 
other than those targeted by the antibody-derived 
"magic bullet'.7 This problem is further exacerbated 
by the fact that the half-lives of both 131I and 123.I are 
relatively inconvenient for optimal use, being too long 
and too short, respectively, and the fact that 13I is also 
a 3 emitter. 1699mTc, 67Ga, and 111 In all suffer from the 
disadvantage that they cannot be bound directly to the 
antibody in a satisfactory fashion and require the use of 
a bifunctional conjugate. The chemistry of such systems 
is furthest advanced in the case of 99mTc, and a number 
of effective ligands, are now available for the purpose of 
99mTc administration.2-12, 18 This particular radioiso 
tope, however, suffers from the serious disadvantage of 
having a very short half-life which makes it technically 
very difficult to work with. Both 67Ga and 111 In have 
longer half-lives. In addition, both possess desirable 
emission energies. Unfortunately, both are "hard' cati 
ons with high charge density in their most common 
trivalent forms. Applications of these radioisotopes in 
RID therefore requires the use of ligands which are 
capable of forming stable, nonlabile complexes with 
these cations under physiological conditions. Although 
considerable effort has been devoted to the develop 
ment of DTPA-like systems19 which would be suitable 
for 11 In (and, perhaps, 67Gat) binding and anti 
body functionalization, in all cases the complexes 
formed are too labile for safe and effective clinical 
use.20 Indeed, at the present time, no suitable ligands 
exist for either 111n + or 67Gah which form stable 
nonlabile complexes and which might be suitable for 
radioimmunological applications. As described else 
where herein texaphyrin forms a kinetically and hydro 
lytically stable complex with Int. Such a ligand sys 
tem could be elaborated and serve as the critical core of 
a bifunctional conjugate for use in In-based RID. 
Many of the same considerations hold true for radi 
oisotope-based therapy as do for radioisotope-based 
diagnostics: An ideal isotope must also be readily avail 
able under clinical conditions (i.e. from a simple decay 
based generator),? possess a reasonable half-life (i.e. on 
the order of 6 hours to 4 weeks), and decay to stable 
products. In addition, the radioisotope must provide 
good ionizing radiation (i.e. in the 300 KeV to 3 MeV 
range). In practice this means using either an a emitter 
or medium to high energy gemitter. 16 Although few a 
emitters are available for therapeutic use (2At is an 
exception), a fair number of g emitters, including 131I, 
are currently receiving attention as possible candidates 
for RIT. Among the more promising, are 186Re (t=90 
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h, 67Cu (t=58.5 h), and 90Y (t=65 h). Of these, 90Y is 
currently considered the best, 6.21 with an emission 
energy of 2.28 MeV, it is calculated to deliver roughly 
3 to 4 times more energy (dose) to the tumor per nano 
mole than either 186Re or 67Cu. Unfortunately, at the 
present time, good immuno-compatible chelands exist 
for only 186Re and 67Cu: The former may be attached 
using the same ligands as were developed for 99mTc, 18 
and the latter via the rationally-designed activated por 
phyrins developed by Prof. Lavallee of Hunter College 
and the Los Alamos INC-11 team.15 Although these 
new porphyrin-based systems, in particular, show real 
promise, being apparently far superior to the existing 
DTPA or DOTA-type systems,14 further benefits 
should be derived from a bifunctional conjugate which 
is capable of forming stable, nonlabile complexes with 
'Y' (which cannot be done with porphyrins). The 
texaphyrin ligand of the present invention not only 
forms stable complexes with Int but also binds Y3+ 
effectively. A texaphyrin-type bifunctional conjugate 
should be developed for use in 11 In-based RID and 
could also find important application in 90Y-based RIT. 
This application outlines ways in which such putative 
bifunctional conjugates may be prepared. 
The observation that complexes of both Y3+ and 
In may be prepared augurs well for the use of texa 
phyrin-type systems as conjugates in immunological 
applications: Both 90Y and 111 In could conceivably be 
attached to an antibody of choice using a functionalized 
texaphyrin. In this regard it is important to note that 
both the Y- and In complexes of texaphyrin are 
formed rapidly (insertion and oxidation times are less 
than 3 hours) from the methylene-linked reduced pre 
cursor, and are hydrolytically stable in 1:1 methanol 
water mixtures (the half-lives for decomplexation and 
/or ligand decomposition exceed 3 weeks in both cases. 
A further advantage of having developed or develop 
ing a wide variety of solubilized texaphyrins, such as 
those shown in FIGS. 31 and 27, is that many of these 
would be suitable for further functionalization. For 
instance, treatment of texaphyrins 7E or 26D with thio 
nyl chloride or p-nitrophenol acetate would generate 
activated acyl species suitable for attachment to mono 
clonal antibodies or other biomolecules of interest. Al 
ternatively, standard in situ coupling methods (e.g. 1, 1'- 
carbonyldiimidazole (CDI)26) could be used to effect 
the same sort of conjugation. In either case, the ability 
to attach and deliver a potent photosensitizer directly to 
a tumor locus could have tremendous potential benefit 
in the treatment of neoplastic disorders. In addition, it is 
precisely this approach which will allow a variety of 
useful radioisotopes such as 90Y and In to be attached 
to a monoclonal antibody. This could prove to be of 
immense benefit in the development of this important 
approach to tumor detection and treatment. 
Literature citations in the following list are incorpo 
rated by reference herein for the reasons cited. 
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We claim: 
1. A method of singlet oxygen production involving 
use of pentadentate expanded porphyrin analog as a 
photosensitizer. 
2. The method of claim 1 wherein the pentadentate 
expanded porphyrin is a texaphyrin or a texaphyrin 
derivative. 
3. A method of light-induced singlet oxygen produc 
tion comprising subjection of an aromatic pentadentate 
expanded porphyrin analog metal complex to light in 












4. The method of claim 3 wherein the aromatic penta 
dentate expanded porphyrin analog is a texaphyrin. 
5. The method of claim 3 wherein the metal is a dia 
magnetic metal. 
6. The method of claim 5 wherein the diamagnetic 
metal is Int3, Zn+2 or Cd-2. 
7. The method of claim 5 wherein the diamagnetic 
metal is a lanthanide metal. 
8. A method of photosensitization comprising the 
production of light-induced singlet oxygen using an 
aromatic pentadentate expanded porphyrin analog 
metal complex having an absorption range from about 
730 to about 770 nanometers and forming long-lived 
triplet states in high yield. 
9. The method of claim 8 wherein the aromatic penta 
dentate expanded porphyrin analog is a texaphyrin. 
10. The method of claim 8 wherein the metal is a 
diamagnetic metal. 
11. The method of claim 10 wherein the diamagnetic 
metal is Ini-3, Zn+2 or Cd-2. 
12. The method of claim 10 wherein the 
metal is a lanthanide metal. 
k s 
diamagnetic 
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